書籍詳細

卵巣の悪性腫瘍

P.12 掲載の参考文献

• 1) Moore KL, Persaud TVN:Before We Are Born:Essentials of Embryology and Birth Defects, 4th ed. 1993, WB Saunders, Philadelphia (瀬口春道, 監訳:受精卵からヒトになるまで-基礎的発生学と先天異常, 原著第4版. 1998, 医歯薬出版, 東京)

• 2) Moore KL, Persaud TVN:The Developing Human. Clinically Oriented Embryology, 5th ed. 1993, WB Saunders, Philadelphia (山村秀樹, 瀬口春道, 訳:ムーア人体発生学, 第5版. 1997, 医歯薬出版, 東京)

• 3) Sadler TW:Langman's Medical Embryology, 7th ed, 1995, Williams & Wilkins, Baltimore (安田峯生, 沢野十蔵, 訳:ラングマン人体発生学, 7版. 1998, 医学書院, 東京)

• 4) 石川 博:女性性器の発生. 現代病理学大系16A, 男性性器・女性性器 I. 1994;pp161-200, 中山書店, 東京

• 5) 緒方 勤:性の決定と性分化異常:性腺形成を主として. 病理診断と分子生物学・遺伝学. 病理と臨床 1996;14(臨時増刊号):60-66

• 6) 吉村泰典:卵胞発育・成熟における卵巣内局所因子の調節機構とその生理学的意義. 日本産科婦人科学会雑誌 1995;47:763-774

• 7) 久具宏司:卵胞発育におけるアポトーシスの意義とその調節機構. 医学のあゆみ 1997;180:716-717

• 8) Gougeon A:Dynamics of human follicular growth. A morphologic prospective. The Ovary (Adashi EY, Leung PCK, eds). 1993;pp21-39, Raven Press, New York

• 9) 藤本征一郎, 首藤聡子, 山田秀人:臨床的な立場からみた卵巣の問題点. 生殖細胞シリーズ18. 臨床科学 1996;32:865-876

• 10) 藤井信吾:女性性器の発生学と婦人科病理学. 日本婦人科病理・コルポスコピー学会雑誌 1989;7:16-32

• 11) Wachtel SS, Ohno S, Koo GC, et al:Possible role for H-Y antigen in the primary determination of sex. Nature 1975;257:235-236

• 12) Sinclair AH, Berta P, Palmer MS, et al:A gene from the human sex-determining region encodes a protein with homology to a conserved DNA-binding motif. Nature 1990;346:240-244

• 13) Koopman P, Munsterberg A, Capel B, et al:Expression of a candidate sex-determining gene during mouse testis difrerentiation. Nature 1990;348:450-452

• 14) Goodfellow PN, Lovell-Badge R:SRY and sex determination in mammals. Annu Rev Genet 1993;27:71-92

• 15) 西森克彦:生殖に関連したTGF-βスーパーファミリーメンバー. 蛋白質核酸酵素1998;43:491-501

• 16) Cate RL, Mattaliano RJ, Hession C, et al:Isolation of the bovine and human genes for mullerian inhibiting substance and expression of the human gene in animal cells. Cell 1986;45:685-698

• 17) Donahoe PK, Cate RL, MacLaughlin DT, et al:Mullerian inhibiting substance:Gene structure and mechanism of action of a fetal regressor. Recent Prog Horm Res 1987;43:431-467

• 18) Haqq CM, King CY, Ukiyama E, et al:Molecular basis of mammalian sexual determination:Activation of mullerian inhibiting substance gene expression by SRY. Science 1994;266:1494-1500

• 19) Gustafson ML, Lee MM, Scully RE, et al:Mullerian inhibiting substance as a marker for ovarian sex-cord tumor. N Engl J Med 1992;326:466-471

• 20) Giwercman A, Grindsted J, Hansen B, et al:Testicular cancer risk in boys with maldescended testis:A cohort study. J Urol 1987;138:1214-1216

• 21) 塙 嘉之:小児癌と奇形. 広範囲症候群. 日本臨牀 1987;45(春季増刊):143

• 22) Noguchi M, Sato M, Mori N, et al:Cooperative roles of oocyte and follicle in ovarian parthenogenesis and teratocarcinogenesis in mice:Evidence from chimeric mice. Biology of the Germ Line-In Animals and Man (Mohri H, Takahashi M, Tachi C, eds). 1993;pp271-283, Japan Sci Soc Press, Tokyo

• 23) 野口基子:生殖細胞の形成, 腫瘍形成. 生殖細胞-形態から分子へ(岡田益吉, 長濱嘉孝, 編著). 1996;pp126-142, 共立出版, 東京

• 24) Ohama K, Nomura K, Okamoto E, et al:Origin of immature teratoma of the ovary. Am J Obstet Gynecol 1985;152:896-900

• 25) 手島伸一, 下里幸雄, 清水興一, ほか:小児の胚細胞腫瘍の病理. 病理と臨床 1985;3:389-394

P.13 掲載の参考文献

• 1) 森 崇英, 山村研一, 編:生殖と発生. 現代医学の基礎 5. 1999, 岩波書店, 東京

P.32 掲載の参考文献

• 1) 福田勝洋:疫学. 新衛生公衆衛生学(館正知, 岡田 晃, 編). 1994;pp167-206, 南山堂, 東京

• 2) 厚生省大臣官房統計情報部, 編:疾病, 傷害および死因統計分類提要, 第2巻. 1993;p105, 厚生統計協会, 東京

• 3) 厚生統計協会:国民衛生の動向. 厚生の指標(臨時増刊)1997;44:75

• 4) 日本産科婦人科学会・日本病理学会, 編:卵巣腫瘍取扱い規約 第1部, 組織分類ならびにカラーアトラス. 1990;p49, 金原出版, 東京

• 5) 加藤 俊:卵巣腫瘍登録委員会報告. 日本産科婦人科学会雑誌1983;35:1693

• 6) 友田 豊:卵巣癌における治療上の問題点. 産婦人科の進歩1990;42:61-66

• 7) Narod SA, Madlensky L, Bradley L, et al:Hereditary and familial ovarian cancer in southern Ontario, Cancer 1994;74:2341-2346

• 8) American Society of Clinical Oncology:Statement of the American Society of Clinical Oncology:Genetic testing for cancer susceptibility, adopted on February 20, 1996. J Clin Oncol 1996;14:1730-1736

• 9) Boyd J:Molecular genetics of hereditary ovarian cancer. Oncology 1998;12:399-406

• 10) Godard B, Foulkes WD, Provencher D, et al:Risk factors for familial and sporadic ovarian cancer among French Canadians:A case-control study. Am J Obstet Gynecol 1998;179:403-410

• 11) Bewtra C, Watson P, Conway T, et al:Hereditary ovarian cancer:A clinicopathological study. Int J Gynecol Pathol 1992;11:180-187

• 12) Lynch HT, Watson P, Bewtra C, et al:Hereditary ovarian cancer. Heterogeneity in age at diagnosis. Cancer 1991;67:1460-1466

• 13) UICC:Trends in Cancer Incidence and Mortality (Coleman MP, Esteve J, Damiecki P, et al, eds). 1993, IARC, Lyon

• 14) IARC:Cancer Incidence in Five Continents (Parkin DM, Whelan SL, Ferlay J, et al, eds), vol 7. 1997, IARC, Lyon

• 15) Tominaga S, Kuroishi T, Aoki K, eds:Cancer Mortality Statistics in 33 Countries 1953-1992. 1998;p76, Roppo Shuppan, Nagoya

• 16) 厚生省大臣官房統計情報部:平成8年人口動態統計, 上巻. 1996, 厚生統計協会, 東京

• 17) Rothman KJ, Greenland S:Modern Epidemiology, 2nd ed. 1998;p49, Lippincott-Raven, Philadelphia

• 18) Struewing JP, Hartge P, Wacholder S, et al:The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-1408

• 19) Easton DF, Steele L, Fields P, et al:Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet 1997;61:120-128

• 20) Watson P, Lynch HT:Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 1993;71:677-685

• 21) Kerlikowske K, Brown JS, Grady DG:Should women with familial ovarian cancer undergo prophylactic oophorectomy? Obstet Gynecol 1992;80:700-707

• 22) Mink PJ, Folsom AR, Sellers TA, et al:Physical activity, waist-to-hip ratio, and other risk factors for ovarian cancer:A follow-up study of older women. Epidemiology 1996;7138-45

• 23) Risch HA, Marrett LD, Jain M, et al:Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study. Am J Epidemiol 1996;144:363-372

• 24) Mourant AE:Blood Groups and Diseases:A Study of Associations of Diseases with Blood Groups and Other Polymorphisms. 1978, Oxford University Press, New York, Toronto

• 25) Bjorkholm E:Blood group distribution in women with ovarian cancer. Int J Epidemiol 1984;13:15-17

• 26) Henderson J, Seagroatt V, Goldacre M:Ovarian cancer and ABO blood groups. J Epidemiol Community Health 1993;47:287-289

• 27) Chen Y, Wu PC, Lang JH, et al:Risk factors for epithelial ovarian cancer in Beijing, China. Int J Epidemiol 1992;21:23-29

• 28) La Vecchia C, Decarli A, Franceschi S, et al:Age at first birth and the risk of epithelial ovarian Cancer. J Natl Cancer Inst 1984;73:663-666

• 29) Kvale G, Heuch I, Nilssen S, et al:Reproductive factors and risk of ovarian cancer:A prospective study. Int J Cancer 1988;42:246-251

• 30) Negri E, Franceschi S, Tzonou A, et al:Pooled analysis of 3 European case-control studies:I. Reproductive factors and risk of epithelial ovarian cancer. Int J Cancer 1991;49:50-56

• 31) Whittemore AS, Harris R, Itnyre J, et al:Characteristics relating to ovarian cancer risk:Collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Am J Epidemiol 1992;136:1184-1203

• 32) Harlow BL, Weiss NS, Roth GJ, et al:Case-control study of borderline ovarian tumors:Reproductive history and exposure to exogenous female hormones. Cancer Res 1988;48:5849-5852

• 33) Harris R, Whittemore AS, Itnyre J, et al:Characteristics relating to ovarian cancer risk:Collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white women. Am J Epidemiol 1992;136:1204-1211

• 34) Risch HA, Weiss NS, Lyon JL, et al:Events of reproductive life and the incidence of epithelial ovarian cancer. Am J Epidemiol 1983;117:128-139

• 35) Tavani A, Negri E, Franceschi S, et al:Risk factors for epithelial ovarian cancer in women under age 45. Eur J Cancer 1993;29A:1297-1301

• 36) Rossing MA, Daling JR, Weiss NS, et al:Ovarian tumors in a cohort of infertile women. N Engl J Med 1994;331:771-776

• 37) International Agency for Research on Cancer Monograph, 1998. http://19351. 164. 11

• 38) Wu ML, Whittemore AS, Paffenbarger RS Jr, et al:Personal and environmental characteristics related to epithelial ovarian cancer. I. Reproductive and menstrual events and oral contraceptive use. Am J Epidemiol 1988;128:1216-1227

• 39) Shu XO, Brinton LA, Gao YT, et al:Population-based case-control study of ovarian cancer in Shanghai. Cancer Res 1989;49:3670-3674

• 40) Tzonou A, Day NE, Trichopoulos D, et al:The epidemiology of ovarian cancer in Greece:A case-control study. Eur J Cancer Clin Oncol 1984;20:1045-1052

• 41) McGowan L, Parent L, Lednar W, et al:The woman at risk for developing ovarian cancer. Gynecol Oncol 1979;7:325-344

• 42) Hildreth NG, Kelsey JL, LiVolsi VA, et al:An epidemiologic study of epithelial carcinoma of the ovary. Am J Epidemiol 1981;114:398-405

• 43) Franceschi S, La Vecchia C, Helmrich SP, et al:Risk factors for epithelial ovarian cancer in Italy. Am J Epidemiol 1982;115:714-719

• 44) Booth M, Beral V, Smith P:Risk factors for ovarian cancer:A case-control study. Br J Cancer 1989;60:592-598

• 45) Parazzini F, La Vecchia C, Negri E, et al:Menstrual factors and the risk of epithelial ovarian cancer. J Clin Epidemiol 1989;42:443-448

• 46) Casagrande JT, Pike MC, Ross RK, et al:"Incessant ovulation" and ovarian cancer. Lancet 1979;ii:170-173

• 47) Mori M, Harabuchi I, Miyake H, et al:Reproductive, genetic, and dietary risk factors for ovarian cancer. Am J Epidemiol 1988;128:771-777

• 48) Gross AJ, Berg PH:A meta-analytical approach examining the potential relationship between talc exposure and ovarian cancer. J Expo Anal Environ Epidemiol 1995;5:181-195

• 49) Weiss NS, Cook LS, Farrow DC, et al:Ovarian cancer. Cancer Epidemiology and Prevention (Schottenfeld D, Fraumeni JF Jr, eds), 2nd ed. 1996;pp1040-1057, Oxford University Press, New York

• 50) Bofretta P, Andersen A, Lynge E, et al:Employment as hairdresser and risk of ovarian cancer and non-Hodgkin's lymphomas among women. J Occup Med 1994;36:61-65

• 51) Dich J, Zahm SH, Hamberg A, et al:Pesticides and cancer. Cancer Causes Control 1997;8:420-443

• 52) World Cancer Research Fund/American Institute for Cancer Research:Food, nutrition and the prevention of cancer:A global perspective (Potter JD, ed). 1997, American Institute for Cancer Research, Washington DC

• 53) Irwin KL, Weiss NS, Lee NC, et al:Tubal sterilization, hysterectomy, and the subsequent occurrence of epithelial ovarian cancer. Am J Epidemiol 1991;134:362-369

• 54) Weiss NS, Harlow BL:Why does hysterectomy without bilateral oophorectomy influence the subsequent incidence of ovarian cancer? Am J Epidemiol 1986;124:856-858

• 55) Whittemore AS, Wu ML, Paffenbarger RS Jr, et al:Personal and environmental characteristics related to epithelial ovarian cancer. II. Exposures to talcum powder, tobacco, alcohol, and coffee. Am J Epidemiol 1988;128:1228-1240

• 56) Hankinson SE, Hunter DJ, Colditz GA, et al:Tubal ligation, hysterectomy, and risk of ovarian cancer:A prospective study. JAMA 1993;270:2813-2818

• 57) Hartge P, Hoover R. , McGowan L, et al:Menopause and ovarian cancer. Am J Epidemiol 1988;127:990-998

• 58) Parazzini F, Negri E, La Vecchia C, et al:Hysterectomy, oophorectomy, and subsequent ovarian cancer risk. Obstet Gynecol 1993;81:363-366

• 59) Center for disease control cancer and steroid hormone study:The reduction in risk of ovarian cancer associated with oral-contraceptive use. N Engl J Med 1987;316:650-655

• 60) Risch HA, Marrett LD, Howe GR:Parity, contraception, infertility, and the risk of epithelial Ovarian Cancer. Am J Epidemiol 1994;140:585-597

• 61) Rosenberg L, Palmer JR, Zauber AG, et al:A case-control study of oral contraceptive use and invasive epithelial ovarian cancer. Am J Epidemiol 1994;139:654-661

• 62) Purdie D, Green A, Bain C, et al:Reproductive and other factors and risk of epithelial ovarian cancer:An Australian case-control study. Survey of Women's Health Study Group. Int J Cancer 1995;62:678-684

• 63) Fathalla MF:Incessant ovulation-A factor in ovarian neoplasia? Lancet 1971;ii:163

• 64) Zajicek J:Ovarian cystomas and ovulation, a histogenetic concept. Tumori 1977;63:429-435

• 65) Cramer DW, Welch WR:Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 1983;71:717-721

• 66) Westhoff C, Murphy P, Heller D, et al:Is ovarian cancer associated with an increased frequency of germinal inclusion cysts? Am J Epidemiol 1993;138:90-93

• 67) Venter PF:Ovarian epithelial cancer and chemical carcinogenesis. Gynecol Oncol 1981;12:281-285

P.48 掲載の参考文献

• 1) Jackson SM:Ovarian dysgerminoma in three generations? J Med Genet 1967;4:112-113

• 2) Lewis ACW, Davison BCC:Familial ovarian cancer. Lancet 1969;ii:235-237

• 3) Lynch HT, Albano W, Black L, et al:Familial excess of cancer of the ovary and other anatomic sites. JAMA 1981;245:261-264

• 4) Narod SA, Madrensky L, Bradley L, et al:Hereditary and familial ovarian cancer in Southern Ontario. Cancer 1994;74:2341-2346

• 5) Hall JM, Lee MK, Newman B, et al:Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990;250:1684-1689

• 6) Narod S, Feunteun J, Lynch H, et al:A breast-cancer locus on chromosome 17. Am J Hum Gener 1991;49:352

• 7) Steichen-Gersdorf E, Gallion HH, Ford D, et al:Familial site-specific ovarian cancer is linked to BRCA1 on 17q12-21. Am J Hum Genet 1994;55:870-875

• 8) Miki Y, Swensen J, Shattuck-Eidens D, et al:A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1 Science 1994;266:66-71

• 9) Collins FS:BRCA1-Lots of mutations, lots of dilemmas, N Engl J Med 1996;334:186-188

• 10) Hosking J, Trowsdale J, Nicolai H, et al:Asomatic BRCA1 mutation in an ovarian tumour. Nat Genet 1995;9:343-344

• 11) Merajver SD, Pham TM, Caduff RF, et al:Somatic mutations in the BRCA1 gene in sporadic ovarian tumours, Nat Genet 1995;9:439-443

• 12) Parkin DM, Muir CS:Cancer incidence in five continents. Comparability and quality of data. IARC Sci Publ 1992;120:45-173

• 13) Inoue R, Fukutomi T, Ushijima T, et al:Linkage analysis of BRCA1 in Japanese breast cancer families. Jpn J Cancer Res 1994;85:1233-1239

• 14) Inoue R, Fukutomi T, Ushijima T:Germline mutation of BRCA1 in Japanese breast cancer families. Cancer Res 1995;55:3521-3524

• 15) Matsushima M, Kobayashi K, Emi M, et al:Mutation analysis of BRCA1 gene in 76 Japanese ovarian cancer patients, four germline mutations but no evidence of somatic mutation. Hum Mol Genet 1995;4:1953-1956

• 16) Katagiri T, Emi M, Ito I, et al:Mutations in the BRCA1 gene in Japanese breast cancer patients. Hum Mutat 1996;7:334-339

• 17) Emi M, Matsushima M, Katagiri T, et al:Multiplex mutation screening of the BRCA1 gene in 1000 Japanese breast cancers:2-3% of Japanese breast cancer is attributable to BRCA1 mutations. Jpn J Cancer Res 1998;89(1):12-16

• 18) Takano T, Aida H, Tuneki I, et al:Mutational analysis of BRCA1 gene in ovarian and breast-ovarian cancer families in Japan. Jpn J Cancer Res 1997;88:407-413

• 19) Aida H, Takakuwa K, Tanaka K, et al:Clinical features of ovarian cancer in Japanese women with germ-line mutation of BRCA1. Clin Cancer Res 1998;4:235-240

• 20) Shelling AN, Cooke IE, Ganesan TS:The genetic analysis of ovarian cancer. Br J Cancer 1995;72:521-527

• 21) Klemi PJ, Pylkkanen L, Kiilholma P, et al:p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian cancer. Cancer 1995;76:1201-1208

• 22) Berchuck A, Kamel A, Whitaker R, et al:Overexpression of HER-2/neu is associated with poor survival in advanced ovarian cancer. Cancer Res 1990;50:4087-4091

P.59 掲載の参考文献

• 1) Itoh K, Tilden AB, Balch CM:Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas. Cancer Res 1986;46:3011-3017

• 2) Itoh K, Platsoucas CD, Balch CM:Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and the involvement of the T cell receptor. J Exp Med 1988;168:1419-1441

• 3) Balch CM, Riley LB, Bae YJ, et al:Patterns of human tumor-infiltrating lymphocytes in 120 human cancers. Arch Surg 1990;125:200-205

• 4) Ferrini S, Biassoni R, Moretta A, et al:Clonal analysis of T lymphocytes isolated from ovarian carcinoma ascitic fluid. Phenotypic and functional characterization of T-cell clones capable of lysing autologous carcinoma cells. Int J Cancer 1985;36:337-343

• 5) Loannides CG, Platsoucas CD, Rashed S, et al:Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites. Cancer Res 1991;51:4257-4265

• 6) Peoples GE, Goedegebuure PS, Andrews JVR, et al:HLA-A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer. J Immunol 1993;151:5481-5491

• 7) Peoples GE Davey MP, Goedegebuure PS, et al:T cell receptor Vβ2 and Vβ6 mediate tumor-specific cytotoxicity by tumor-infiltrating lymphocytes in ovarian cancer. J Immunol 1993;151:5472-5480

• 8) Peoples GE, Yoshino I, Douville CC, et al:TCR Vβ3+ and Vβ6+ CTL recognize tumor-associated antigens related to HER2/neu expression in HLA-A2+ ovarian cancers. J Immunol 1994;152:4993-4999

• 9) Fisk B, Blevins TL, Wharton JT, et al:Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 1995;181:2109-2117

• 10) Yamada A, Kawano K, Harashima N, et al:Study of HLA-class I-restriction and directed antigen of cytotoxic T lymphocytes at the tumor sites of ovarian cancer. Cancer Immunol Immunother 1999;48:147-152

• 11) Nakao M, Yamana H, Imai Y, et al:HLA A2601-restricted cytotoxic T lymphocytes recognized a peptide antigen expressed on squamous cell carcinoma. Cancer Res 1995;55:4248-4252

• 12) Hoshino T, Seki N, Kikuchi M, et al:HLA-class I-restricted and tumor-specific CTL in tumor-infiltrating lymphocytes of patients with gastric cancer. Int J Cancer 1997;70:631-638

• 13) Toh U, Yamana H, Nakao M, et al:HLA-class-I-restricted and tumor-specific cytotoxic T lymphocytes from metastatic lymph nodes of esophageal cancers. Cell Immunol 1997;177:137-143

• 14) Gouhara R, Nakao M, Ogata Y, et al:Histocompatibility leukocyte antigen-2402-restricted cytotoxic T lymphocytes recognizing adenocarcinomas in tumor-infiltrating lymphocytes of patients with colon cancer. JJCR 1997;88:198-204

• 15) Seki N, Hoshino T, Kikuchi M, et al:HLA-A locus-restricted and tumor-specific CTL in tumor-infiltrating lymphocytes of patients with non-small lung cancer. Cell Immunol 1997;175:101-110

• 16) Suekane S, Nakao M, Inoue M, et al:Histocompatibility leukocyte antigen-2-restricted and tumor-specific cytotoxic T lymphocytes from tumor-infiltrating lymphocytes of a patient with testicular embryonal cancer. JJCR 1998;89:1180-1189

• 17) Nagai K, Yamada A, Eguchi H, et al:HLA-A2402-restricted and tumor-specific cytotoxic T lymphocytes from tumor-infiltrating lymphocytes of a child with Wilm's tumor. Pediatr Res 1997;42:122-127

• 18) Ioannides CG, Fisk B, Jerome KR, et al:Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J Immunol 1993;151:3693-3703

• 19) 高橋利忠, 辻村邦夫, 小幡裕一:腫瘍抗原に対する宿主抗体産生応答. Immunology Frontier 1998;8:247

• 20) 高橋利忠, 吉川和宏:モノクローナル抗体を基盤とした新しい抗体分子. Immunology Frontier 1998;8:311

• 21) Scott AM, Welt S:Antibody-based immunological therapies. Curr Opin Immunol 1997;9:717-722

• 22) Rughetti A, Turchi V, Ghetti CA, et al:Human B-cell immune response to the polymorphic epithelial mucin. Cancer Res 1993;53:2457-2459

• 23) Sorokine I, Ben-Mahrez K, Bracone A, et al:Presence of circulating anti-c-myb oncogene product antibodies in human sera. Int J Cancer 1991;47:665-669

• 24) Ben-Mahrez K, Sorokine I, Thierry D, et al:Circulating antibodies against c-myc oncogene product in sera of colorectal cancer patients. Int J Cancer 1990;46:35-38

• 25) van der Bruggen P, Traversari C, Chomez P, et al:A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-1647

• 26) Eura M, Ogi K, Chikamatsu K, et al:Expression of MAGE gene family by human head and neck squamous cell carcinomas. Int J Cancer 1995;64:304-308

• 27) Yamada A, Kataoka A, Shichijo S, et al:Expression of MAGE-1, MAGE-2, MAGE-3/-6 and MAGE-4a/-4b genes in ovarian tumors. Int J Cancer 1995;64:388-393

• 28) Toh Y, Yamana H, Shichijo S, et al:Expression of MAGE-1 gene by esophageal carcinomas. Jpn J Canner Res 1995;86:714-717

• 29) Yamashita N, Ishibashi H, Hayashida K, et al:High frequency of the MAGE-1 gene expression in hepatocellular carcinoma. Hepatology 1996;24:1437-1440

• 30) Shichijo S, Yamada A, Sagawa K, et al:Induction of MAGE genes in lymphoid cells by the demethylating agent 5'-Aza-2'-deoxycytidine. JJCR 1996;87:751-756

• 31) Inoue H, Li J, Honda M, et al:Expression of MAGE-1, -2, -3 mRNA in gastric carcinoma. Med Sci Res 1994;22:793-796

• 32) Takahashi K, Shichijo S, Noguchi M, et al:Identification of MAGE-1 and-4 proteins in spermatogonia and primary spermatocytes of testis. Cancer Res 1995;55:3478-3482

• 33) Traversari C, van der Bruggen P, Luescher IF, et al:A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992;176:1453-1457

• 34) Gaugler B, Van den Eynde B, van der Bruggen P, et al:Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994;179:921-930

• 35) van der Bruggen P, Bastin J, Gajewski T, et al:A peptide encoded by human gelle MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 1994;24:3038-3043

• 36) Romero P, Pannetier C, Herman J, et al:Multiple specificities in the repertoire of a melanoma patient's cytolytic T lymphocytes directed against tumor antigen MAGE-1. A1. J Exp Med 1995;182:1019-1028

• 37) Seito D, Morita T, Masuoka K, et al:Polyclonal uses of T-cell receptor (TCR) α and β genes for cytotoxic T lymphocytes in human metastatic melanoma:Possible involvement of TCRα in tumor cell recognition. Int J Cancer 1994;58:497-502

• 38) Guilloux Y, Lucas S, Brichard VG, et al:A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene. J Exp Med 1996;183:1173-1183

• 39) Boel P, Wildmann C, Sensi ML, et al:BAGE:a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 1995;2:167-175

• 40) Ven den Eynde B, Peeters O, De Backer O, et al:A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 1995;182:689 698

• 41) Jager E, Chen YT, Drijfhout JW, et al:Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1;definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitope. J Exp Med 1998;187:265-270

• 42) Kawakami Y, Eliyahu S, Delgado CH, et al:Cloning of the gene coding for a shared human melalloma antigen recogllized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994;91:3515-3519

• 43) Kawakami Y, Eliyahu S, Delgado CH, et al:Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994;91:6458-6462

• 44) Brichard V, Van Pel A, Wolfel T, et al:The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993;178:489-495

• 45) Lupetti R, Pisarra P, Verrecchia A, et al:Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage. J Exp Med 1998;188:1005-1016
  pubmed

• 46) Coulie PG, Brichard V, Van Pel A, et al:A new gene coding tbr a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 19941 180:35-42

• 47) Wang RF, Parkhurst MR, Kawakami Y, et al:Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J Exp Med 1996;183:1131-1140

• 48) Sugita S, Sagawa K, Mochizuki M, et al:Melanocyte lysis by CTL recognizing the MART-1 melanoma antigen in HLA-A2 patients with Vogt-Koyanagi Harada (VKH) disease. Int Immunol 1996;8:799-803

• 49) Rivoltini L, Kawakami Y, Sakaguchi K, et al:Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol 1995;154:2257-2265

• 50) Marincola FM, Rivoltini L, Salgaller ML, et al:Differential anti-MART-1/Melan A CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors:Evidence for in vivo priming by tumor cells. J Immunother Emphasis Tumor Immunol 1996;19:266-277

• 51) Salgaller ML, Afsher A, Marincola FM, et al:Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res 1995;55:4972-4979

• 52) Correale P, Walmsley K, Zaremba S, et al:Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide. J Immunol 1998;161:3186-3194

• 53) Peshwa MV, Shi JD, Ruegg C, et al:Induction of prostate tumor-specilic CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide. Prostate 1998;36:129-138

• 54) Fong L, Ruegg CL, Brockstedt D, et al:Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization. J Immunol 1997;159:3113-3117

• 55) Albert ML, Darnell JC, Bender A, et al:Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med 1998;14:1321-1324

• 56) Robbins PF, El-Gamil M, Li YF, et al:A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 19961;183:1185-1192

• 57) Wolfel T, Hauer M, Schneider J, et al:A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995;269:1281-1284

• 58) Coulie PG, Lehmann F, Lethe B, et al:A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci USA 1995;92:7976-7980

• 59) Wang R-F, Parkhurst MR, Kawakami Y, et al:Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J Exp Med 1996;183:1131-1140

• 60) Brandle D, Brasseur F, Weynants P, et al:A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma. J Exp Med 1996;183:2501-2508

• 61) Mandruzzato A, Brasseur F, Andry G, et al:A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J Exp Med 1997;186:785-793

• 62) Robbins PF, El-Gamil M, Li YF, et al:Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. J Immunol 1995;154:5944-5950

• 63) Peoples GE, Goedegebuure PS, Smith R, et al:Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 1995;92:432-436

• 64) Yoshino I, Goedegebuure PS, Peoples GE, et al:HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res 1994;54:3387-3390

• 65) Hodge JW:Carcinoembryonic antigen as a target for cancer vaccines. Cancer Immunol Immunother 1996;43:127-134

• 66) Apostolopoulos V, Chelvanayagam G, Xing P-X, et al:Anti-MUCI antibodies react directly with MUC1 peptides presented by class I H2 and HLA molecules. J Immunol 1998;161:767-775

• 67) Shichijo S, Nakao T, Imai Y, et al:A gene encoding antigenic peptides ofhuman squamous cell carcinoma recognized by cytotoxic T lymphocytes. J Exp Med 1998;187:277-288

• 68) Kikuchi M, Nakao M, Inoue Y, et al:Identification of a SART-1-derived peptoide capable of inducing the HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes. Int J Cancer 1999;81:459-466

• 69) Matsumoto H, Shichijo S, Kawano K, et al:Expression of SART-1 antigens in uterine cancers. Jpn J Cancer Res 1998;89:1292-1295

• 70) Boon T, van der Bruggen P:Human tumor antigens recognized by T lymphocytes. J Exp Med 1996;183:725-729

• 71) Rosenberg SA:Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 1997;18:175-182

P.74 掲載の参考文献

• 1) 吉田直哉:癌細胞はこう語った-私伝・吉田富三. 1992, 文藝春秋, 東京

• 2) Furth J, Furth OB:Neoplastic diseases produced in mice by general irradiation with X-rays. Am J Cancer 1936;28:54-65

• 3) Hamilton TC:Ovarian cancer, Part 1:Biology. Curr Probl Cancer 1992;16:1-57

• 4) Schiller W:Concepts of a new classification of ovarian tumors. Surg Gynecol Obstet 1940;70:773-782

• 5) Serov SF, Scully RE, Sobin LH:Histological Typing of Ovarian Tumours. 1973, World Health Organization, Geneva

• 6) Murphy ED, Beamer WG:Suggested goals for further research. Biology of Ovarian Neoplasia (Murphy ED, Beamer WG, eds). A Series of Workshops on the Biology of Human Cancer. Report No 11, 1980;pp131-132, International Union Against Cancer, Geneva

• 7) Fox H:Human ovarian tumours:Classification, histogenesis, pathogenesis and criteria for experimental models. Biology of Ovarian Neoplasia (Murphy ED, Beamar WG, eds). A Series of Workshops on the Biology of Human Cancer. Report No 11. 1980;pp22-33, International Union Against Cancer, Geneva

• 8) Workman P, Balmain A, Hickman JA, et al:UKCCCR guidelines for the welfare of animals in experimental neoplasia. Br J Cancer 1988;58:109-113

• 9) Sekiya S, Endoh N, Kikuchi Y, et al:In vitro and vivo studies of experimental ovarian adenocarcinoma in rats. Cancer Res 1979;39:1108-1112

• 10) Nishida T, Oda T, Sugiyama T, et al:Squamous cell carcinoma arising from an epidermoid cyst in the ovary of rat treated with 7, 12-dimethylbenz[a]anthracene. Gann 1982;73:153-157

• 11) Nishida T, Sugiyama T, Katabuchi H, et al:Histologic origin of rat ovarian adenocarcinoma induced by direct application of 7, 12-dimethylbenz[a]anthracene. Acta Obstet Gynaecol Jpn 1986;38:570-574

• 12) Tunca JC, Erturk E, Erturk E, et al:Chemical induction of ovarian tumors in rats. Gynecol Oncol 1985;21:54-64

• 13) Adams AT, Auersperg N:Transformation of cultured rat ovarian surface epithelial cell by Kirsten murine sarcoma virus. Cancer Res 1981;41:2063-2072

• 14) Godwin AK, Testa JR, Handel LM, et al:Spontaneous transformation of rat ovarian surface epithelial cells:Association with cytogenetic changes and implications of repeated ovulation in the etiology of ovarian cancer. J Natl Cancer Inst 1992;84:592-601

• 15) Godwin AK, Testa JR, Hamilton TC:The biology of ovarian cancer development. Cancer 1993;71:530-536

• 16) Fathala MF:Incessant ovulation:A factor in ovarian neoplasia? Lancet 1971;ii:163

• 17) Casagrande JT, Louie EW, Pike MC, et al:"Incessant ovulation" and ovarian cancer. Lancet 1979;ii:170-173

• 18) Russfield AB:Pathology of the endocrine glands, ovary and testis of rats and mice. Pathology of Laboratory Rats and Mice (Cotchin E, Roe FJC, eds). 1967;pp391-467, Blackwell, Oxford, Edinburgh

• 19) Cotchin E:Spontaneous tumors of the uterus and ovaries in animals. Animal Tumors of the Female Reproductive Tract. Spontaneous and Experimental (Cotchin E, Marchant J, eds). 1977;pp26-65, Springer-Verlag, New York, Heidelberg, Berlin

• 20) Nishida T, Sugiyama T, Kataoka A, et al:Histologic characterization of rat ovarian cancer induced by intraovarian insertion of 7, 12-dimethylbenz[a]anthracene-coated suture-Common epithelial tumors of the ovary in rat? Cancer 1998;83:965-970

• 21) Azoury RS, Woodruff JD:Primary ovarian sarcomas. Report of 43 cases from the Emil Nvak Ovarian Tumor Registry. Obstet Gynecol 1971;37:920-941

• 22) Stowe LM, Watt JY:Osteosarcoma of the ovary. Am J Obstet Gynecol 1952;64:422-426

• 23) Hsu C:Endometrial ossification. Br J Obstet Gynaecol 1975;82:836-839

• 24) Shipton EA, Meares SD:Heterotopic bone formation in the ovary. Aust N Z J Obstet Gynaecol 1965;5:100-102

• 25) Climie ARW, Heath LP:Malignant degeneration of benign cystic teratomas of the ovary. Cancer 1968;22:824-832

• 26) Stevens LC:The origin and development of ovarian teratoma in mice. Biology of Ovarian Neoplasia (Murphy ED, Beamer WG, eds). A Series of Workshops on the Biology of Human Cancer. Report No 11. 1980;pp74-81, International Union Against Cancer, Geneva

• 27) 中田大地, 巴 一, 常松 泉, ほか:酵母を用いたラットp53遺伝子の機能的変異検出法の確立. Proceedings of the Japanese Cancer Association. 56th Annual Meeting;1997 Sept 25-271 p306. Kyoto

• 28) Nishida T, Sugiyama T, Kataoka A, et al:Cytotoxic impacts on the tumorigenesis and transplantability of ovarian teratoma in LT/Sv mouse. Oncol Rep 1995;2:1045-1048

• 29) Nishida T, Sugiyama T, Kataoka A, et al:Intrasplenic grafting of ovarian piece containing 7, 12-dimethylbenz[a]anthracene-coated silk suture. Oncol Rep 1998;5:161-163

• 30) Nishida T, Ueyama T, Sugiyama T, et al:Intrasplenic autograft of testicular tissue in rats. Oncol Rep 1998;5:157-159

P.91 掲載の参考文献

• 1) Santesson L, Kottmeier HL:General classification of ovarian tumors. Ovarian Cancer, UICC Monograph Series, vol II. 1968;pp1-8, Springer-Verlag, New York

• 2) Kolstad P, Ludwig H, Ulfelder H:Annual Report on the Results of Treatment in Gynecological Cancer, vol 19. 1985. International Federation of Gynecology and Obstetrics, Stockholm

• 3) Serov SF, Scully RE, Sobin LH:Histological typing of ovarian tumours. International Histologic Classification of Tumours, No 9. 1973, WHO, Geneva

• 4) Scully RE:Proposed new ISGYP-WHO classification of tumours of the ovary. 1989 (personal Communication)

• 5) 日本産科婦人科学会・日本病理学会, 編:卵巣腫瘍取扱い規約-第1部:組織分類ならびにカラーアトラス. 1990, 金原出版, 東京

• 6) Scully RE:Tumors of the Ovary and Maldeveloped Gonad. 1979, Armed Forces Institute of Pathology, Washington

• 7) Peters H, Mcnatty KP:The development of the ovary in the embryo. The Ovary. 1980;pp1-11, Granada Publishing, London, Tronto, Sydney, New York

• 8) Gillman J:The development of gonads in man, with a consideration of the role fetal endocrines and the histogenesis of ovarian tumors. Contr Embryol Carnegie Instn 1948;32:81-131

• 9) Forabosco A, Storza C, dePol A, et al:Morphometric study of the human neonatal ovary. Anat Rec 1991;231:201-208

• 10) O'Rahilly R, Muller F:Human Embryology & Teratology, 2nd ed. 1994;pp191-315, Wiley-Liss, New York

• 11) Satoh M:Histogenenesis and organogenesis of the gonad in human embryos. J Anat 1991;177:85-107

• 12) 寺島芳輝:卵巣腫瘍の組織発生. 産婦人科MOOK 28, 卵巣腫瘍. 1984;pp9-29, 金原出版, 東京

• 13) Piver MS:Ovarian malignancies. Current Reviews in Obstetrics & Gynecology, No 4. 1983, Churchill Livingstone, Edinburgh, London, Merbourne, New York

P.92 掲載の参考文献

• 1) 上田外幸:卵巣腫瘍の分類. 産婦人科治療1990;61:129-136

• 2) Gompel C, Silverberg SG:Pathology in Gynecology and Obstetrics, 4th ed. 1994, JB Lippincott, Philadelphia

• 3) 寺島芳輝:卵巣腫瘍の組織発生と分類(1)-形態学を中心に. 現代産科婦人科学大系, 年刊追補'76-B, 1977;pp173-228, 中山書店, 東京

P.109 掲載の参考文献

• 1) Taylor HC:Malignant and semimalignant tumors of the ovary. Surg Gynecol Obstet 1929;48:204-230

• 2) Kraus TT:Gynecologic Pathology. 1967;pp330-337, The Mosby, St Louis

• 3) Santesson L, Kottmeier HL:General classification of ovarian tumors. Ovarian Cancer. UICC Monograph Series, vol 11 (Gentil F, Junquera AC, eds). 1968;pp1-8, Springer-Verlag, New York

• 4) International Federation of Gynecology and Obstetrics:Classification and staging of malignant tumours in the female pelvis. Acta Obstet Gynecol Scand 1971;50:1-7

• 5) Julian CC, Woodruff JD:The biologic behavior of low-grade papillary serous carcinoma of the ovary. Obstet Gynecol 1972;40:860-867

• 6) Nikolas A, Janovski NA, Paramandhan TL:Tumors and tumor-like conditions of the ovaries, fallopian tubes and ligaments of the uterus. Ovarian Tumors. 1973;pp12-46, Georg Thieme, Stuttgart

• 7) Serov SF, Scully RE:International Histological Classification of Tumors, vol 9, Histological Typing of Ovarian Tumors. 1973;pp37-42, World Health Organization, Geneva

• 8) Fox H, Langeey FA:Tumors of the Ovary. 1976;pp43-46, William Heinemann Medical Books, London

• 9) Czernobilsky B:Primary epithelial tumors of the ovary. Pathology of the Female Genital Tract (Blaustein A, ed). 1977;pp456-460, Springer-Verlag, New York

• 10) 日本産科婦人科学会, 日本病理学会, 編:卵巣腫瘍取扱い規約-第1部:組織分類ならびにカラーアトラス, 第1版. 1990;pp21-26, 金原出版, 東京

• 11) 田口孝爾:卵巣の良性腫瘍-病理. 新女性医学大系 39, 産婦人科の良性腫瘍子宮筋腫, 卵巣嚢腫, 乳房腫瘍. 1999;pp46-62, 中山書店, 東京

• 12) Tavassoli FA:Serous tumor of low malignant potential with early stromal invasion (serous LMP with microinvasion). Med Pathol 1988;1:407-414

• 13) Bell DA, Scully RE:Ovarian serous borderline tumors with stromal microinvasion:A report of 21 cases. Hum Pathol 1990;21:397-403

• 14) Nayar R, Siriaunkgul S, Robbins KM, et al:Microinvasion in low malignant potential tumors of the ovary. Hum Pathol 1996;27:521-527

• 15) Kennedy AW, Hart WR:Ovarian papillary serous tumors of low malignant potential (serous borderline tumors). A long term follow-up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma. Cancer 1996;78:278-286

• 16) De Nictolis M, Montironi R, Tommasoni S, et al:Serous borderline tumors of the ovary:A clinicopathologic, immunohistochemical, and quantitative study of 44 cases. Cancer 1992;70:152-160

• 17) Michael H, Roth LM:Invasive and noninvasive implants in ovarian serous tumors of low malignant potential. Cancer 1986;57:1240-1247

• 18) 田口孝爾:卵巣-境界悪性と初期浸潤癌の鑑別点. 日本婦人科病理・コルポスコピー学会雑誌 1993;11:153-158

• 19) 田口孝爾:卵巣・栄養膜. 腫瘍病理アトラス-境界病変と鑑別診断(赤木忠厚, 牛込新一郎, 森脇昭介, 編). 1997;pp187-206, 医歯薬出版, 東京

• 20) Auer J, Hoeg K, Kolstad P:Clinical and histologic studies of ovarian carcinoma. Obstet Gynecol 1971;37:1-9

• 21) Kliman L, Rome RM, Fortune DW:Low malignant potential tumors of the ovary:A study of 76 cases. Obstet Gynecol 1986;68:338-344

• 22) Russell P:The pathological assessment of ovarian neoplasms. II:The proliferating "epithelial" tumours. Pathology 1979;11:251-282

• 23) Bell DA:Ovarian surface epithelial-stromal tumors. Hum Pathol 1991;22:750-762

• 24) Bell DA, Weinstock MA, Scully RE:Peritoneal implants of ovarian serous borderline tumors:Histologic features and prognosis. Cancer 1988;62:2121-2222

• 25) Bostwick DG, Tazellaar HD, Ballon SC, et al:Ovarian epithelial tumors of borderline malignancy. A clinical and pathologic study of 109 cases. Cancer 1986;58:2052-2065

• 26) Katzenstein A-LA, Mazur MT, Morgan TE, et al:Proliferative serous tumors of the ovary. Histologic features and prognosis. Am J Surg Pathol 1978;2:339-355

• 27) Leake JF, Currie JL, Rosenstein NB, et al:Long-term follow-up of serous ovarian tumors of low malignant potential. Gynecol Oncol 1992;47:150-158

• 28) Basrnhill D, Heller P, Brzozowski P, et al:Epithelial ovarian carcinoma of low malignant potential. Obstet Gynecol 1985;65:53-59

• 29) Nakashima N, Nagasaka T, Oiwa N, et al:Ovarian epithehal tumors borderhne malignancy in Japan. Gynecol Oncol 1990;38:90-98

• 30) Nation JG, Krepart GV:Ovarian carcinoma of low malignant potential:Staging and treatment. Am J Obster Gynecol 1986;154:290-293

• 31) Lauchlan SC:The secondary mullerian system revisited. Int J Gynecol Pathol 1994;13:73-79

• 32) Tamakoshi K, Kikkawa F, Nakashima N, et al:Clinical behavior of borderline ovarian tumors:A study of 150 cases. J Surg Oncol 1997;64:147-152

• 33) Yazigi R, Sandstad J, Munoz AK:Primary staging in ovarian tumors of low malignant potential. Gynecol Oncol 1988;31:402-408

• 34) Leake JF, Rader JS, Woodrufr JD, et al:Retroperitoneal lymphatic involvement with epithelial ovarian tumors of low malignant potential. Gynecol Oncol 1991;42:124-130

• 35) Tan LK, Flynn SD, Carcangiu ML:Ovarian serous borderline tumors with lymph node involvement. Clinicopathologic and DNA content study of seven cases and review of the literature. Am J Surg Pathol 1994;18:904-912

• 36) Gershenson DM, Silva EG, Levy L, et al:Ovarian serous borderline tumors with invasive peritoneal implants. Cancer 1998;82:1096-1103

• 37) Silva EG, Kurman RJ, Russell P, et al:Symposium:Ovarian tumors of borderline malignancy. Int J Gynecol Pathol 1996;15:281-302

• 38) Seidman JD, Kurman RJ:Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases. Am J Surg Pathol 1996;20:1331-1345

• 39) Russell P:Surface epithelial-stromal tumors of the ovary. Blaustein's Pathology of the Female Genital Tract (Kuman RJ, ed), 4th ed. 1991;pp705-782, Springer-Verlag, New York

• 40) Genadry R, Poliakoff S, Rotmensch J, et al:Primary, papillary peritoneal neoplasia. Obstet Gynecol 1981;58:730-734

• 41) Russell P:Borderhne epithelial tumours of the ovary:A conceptual dilemma. Clin Obstet Gynecol 1984;11:259-277

• 42) Burks RT, Sherman ME, Kurman RJ:Micropapillary serous carcinoma of the ovary:Distinctive low-grade carcinoma related to serous borderline tumors. Am J Surg Pathol 1996;20:1319-1330

• 43) Katabuchi H, Tashiro H, Cho KR, et al:Micropapillary serous carcinoma of the ovary:An immunohistochemical and mutational analysis of p53. Int J Gynecol Pathol 1998;17:54-60

• 44) Drescher CW, Flint A, Hopkins MP, et al:Prognostic significance of DNA content and nuclear morphology in borderline ovarian tumors. Gynecol Oncol 1993;48:242-246

• 45) Harlow BL, Fuhr JE, McDonald TW, et al:Flow cytometry as a prognostic indicator in women with borderline epithelial ovarian tumors. Gynecol Oncol 1993;50:305-309

• 46) Kuprzjanczyk J, Bell DA, Yandell DW, et al:p53 expression in ovarian borderline tumors and stage I carcinomas. Am J Clin Pathol 1994;102:671-676

• 47) Seidman JD, Frishman DM, Norris HJ, et al:Expression of the HER-2/neu proto-oncogene in serous ovarian neoplasms. Cancer 1992;70:2857-2860

• 48) Seidman JD, Norris HJ, Griffin JL, et al:DNA flow cytometric analysis ofserous ovarian tumors of low malignant potential. Cancer 1993;71:3947-3951

• 49) Wertheim I, Muto MG, Welch WR, et al:p53 gene mutation in human borderline epithelial ovarian tumors. J Natl Cancer Inst 1994;86:1549-1551

• 50) Rutgers JL, Scully RE:Ovarian mullerian mucinous papillary cystadenomas of borderline malignancy:A clinicopathologic analysis. Cancer 1988;61:340-348

• 51) Fenoglio C, Cottral G, Ferenczy A, et al:Mucinous tumors of the ovary. III. Histochemical studies. Gynecol Oncol 1976;4:151-157

• 52) Klemi PJ:Pathology of mucinous ovarian cystadenomas. l. Argyrophil and argentaffine cells and epithelial mucosubstances. Acta Pathol Microbiol Scand [A] 1978;86A:465-470

• 53) Klemi PJ, Nevalainen T:Pathology of mucinous ovarian cystadenomas. 2. Ultrastructural findings. Acta Pathol Microbiol Scand [A] 1978;86A:471-481

• 54) Aguirre P, Daval Y, Scully R, et al:Mucinous tumors of the ovary with argyrophil cells. An immunohistochemical analysis. Am J Surg Pathol 1984;8:334-356

• 55) Siriaunkgul S, Robbins KM, McGowan L, et al:A clinicopathologic study of 54 tumors of intestinal and mullerian type. Int J Gynecol Pathol 1995;14:198-208

• 56) Guerieri C, Hogberg T, Wingren S, et al:Mucinous borderline and malignant tumors of the ovary. A clinicopathologic and DNA ploidy study of 92 cases. Cancer 1994;74:2329-2340

• 57) Ruters J, Bell DA:Immunohistochemical characterization of ovarian borderline tumors of intestinal and mullerian types. Mod Pathol 1992;5:205-214

• 58) Rutgers JL, Bell DA:Immunohistochemical characterization of ovarian borderline tumors of intestinal and mullerian types. Mod Pathol 1992;5:367-371

• 59) Nomura K, Aizawa S:Clinicopathologic and much histochemical analyses of 90 cases of ovarian mucinous borderline tumors of intestinal and mulerian types. Pathol Int 1996;46:575-580

• 60) Hart W, Norris H:Borderline and malignant mucinous tumors of the ovary. Histologic criteria and clinical behavior. Cancer 1973;31:1031-1045

• 61) Hart W:Ovarian epithelial tumors of borderline malignancy (carcinoma of low malignant potential). Hum Pathol 1977;8:541-549

• 62) Michael H, Sutton G, Roth LM:Ovarian carcinoma with extracellular mucin production:Reassessment of "pseudomyxoma ovarii et peritonei". Int J Gynecol Pathol 1987;6:298-312

• 63) Prayson RA, Hart WR, Petras RE, et al:Pseudomyxoma peritonei. A clinicopathologic study of 19 cases with emphasis on site of origin and nature of associated ovarian tumors. Am J Surg Pathol 1994;18:591-603

• 64) Young RH, Gilks CB, Scully RE:Mucinous tumors of the appendix associated with mucinous tumors of the ovary and pseudomyxoma peritonei. A clinicopathological analysis of 22 cases supporting an origin in the appendix. Am J Surg Pathol 1991;15:415-429

• 65) Campbell JS, Lou P, Ferguson JP, et al:Pseudomyxoma peritonei et ovarii with occult neoplasms of appendix. Obstet Gynecol 1973;42:897-902

• 66) Ronnett BM, Zahn CM, Kurman RJ, et al:Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to "pseudomyxoma peritonei". Am J Surg Pathol 1995;19:1390-1408

• 67) Seidman JD, Elsayed AM, Sobin LH, et al:Association of mucinous tumors of the ovary and appendix. A clinicopathologic study of 25 cases. Am J Surg Pathol 1993;17:22-34

• 68) Sumithran E, Sunsil BJ:Concomitant mucinous tumors of appendix and ovary. Result of a neoplastic field change. Cancer 1992;70:2980-2983

• 69) Sumithran E, Susil BJ:Concomitant mucinous tumors of appendix and ovary. Result of a neoplastic field change. Cancer 1992;70:2980-2983

• 70) Kahn MA, Demopoulos RI:Mucinous ovarian tumors with pseudomyxoma peritonei:A clinicopathological study. Int J Gynecol Pathol 1992;11:15-23

• 71) Sandenbergh HA, Woodrufr JD:Histogenesis of pseudomyxoma peritonei. Review of 9 cases. Obstet Gynecol 1977;49:339-345

• 72) Norris HJ:Proliferative endometrioid tumors and endometrioid tumors of low malignant potential of the ovary. Int J Gynecol Pathol 1993;12:134-140

• 73) Roth LM, Czernobilsky B, Langley FA:Ovarian endometrioid adenofibromatous and cystadenofibromatous tumors:Benign, proliferating, and malignant Cancer 1981;48:1838-1845

• 74) Bell DA, Scully RE:Atypical and borderline endometroid adenofibromas of the ovary. A report of 27 cases. Am J Surg Pathol 1985;9:205-214

• 75) Snyder RR, Norris HJ, Tavassoli F:Endometrioid proliferative and low malignant potential tumors of the ovary. A clinicopathologic study of 46 cases. Am J Surg Pathol 1988;12:661-671

• 76) Russell P:The pathological assessment of ovarian neoplasms. II. The proliferating 'epithelial' tumours. Pathology 1979;11:251-282

• 77) Roth LM, Langley FA, Fox H, et al:Ovarian clear cell adenofibromatous tumors. Benign, of low malignant potential, and associated with invasive clear cell carcinoma. Cancer 1984;53:1156-1163

• 78) Bell DA, Scully RE:Benign and borderline clear cell adenofibromas of the ovary. Cancer 1985;56:2922-2931

• 79) Michael H, Roth LM, Kotylo P:Recent developments in the pathology of ovarian epithelial tumors of low malignant potential and related neoplasms. Pathol Annual, part 2 (Rosen PP, Fechner RE, eds). 1993;pp1-22, Appleton & Lange, Norwalk

• 80) 中島伸夫:卵巣境界悪性腫瘍Borderline tumor(WHO)の頻度, 組織診断とその予後. 病理と臨床1988;6:1145-1153

• 81) Roth LM, Dallenbach-Hellweg G, Czernobilsky B:Ovarian Brenner tumors. I. Metaplastic, proliferating, and of low malignant potential. Cancer 1985;56:582-591

• 82) Trebeck CE, Friedlander ML, Russell P, et al:Brenner tumours of the ovary:A study of the histology, immunohistochemistry and cellular DNA content in benign, borderline and malignant ovarian tumours. Pathology 1987;19:241-246

• 83) Roth LM, Czernobilsky B:Ovarian Brenner tumors. II. Malignant. Cancer 1985;56:592-601

P.148 掲載の参考文献

• 1) Scully RE, Young RH, Clement PB:Tumors of the ovary and maldeveloped gonads, fallopian tube, and broad ligament. Atlas of Tumor Pathology, 3rd series, Fascicle No 23. 1998;pp51-331, Armed Forces Institute of Pathology, Washington DC

• 2) Scully RE:Histological Typing of Ovarian Tumours. WHO International Histological Classification of Tumours. 1999, Springer, Berlin

• 3) 日本産科婦人科学会, 日本病理学会, 編:卵巣腫瘍取扱い規約-第1部:組織分類ならびにカラーアトラス. 1990, 金原出版, 東京

• 4) Nakashima N, Nagasaka S, Fukata S, et al:Study ofovarian tumors treated at Nagoya University Hospital, 1965-1988. Gynecol Oncol 1990;37:103-111

• 5) Gershenson DM, Silva EG:Serous ovarian tumors of low malignant potential with peritoneal implants. Cancer 1990;65:578-585

• 6) Katzenstein AL, Mazur MT, Morgan TE, et al:Proliferative serous tumors of the ovary. Histologic features and prognosis. Am J Surg Pathol 1978;2:339-355

• 7) Gilks CB, Bell DA, Scully RE:Serous psammocarcinoma of the ovary and peritoneum. Int J Gynecol Pathol 1990;9:110-121

• 8) Young RH, Scully RH:Metastatic tumor of the ovary. Blaustein's Pathology of the Female Genital Tract (Kurman Rj, ed), 4th ed. 1994;pp953-956, Springer-Verlag, New York

• 9) Hart WR, Norris HJ:Borderline and malignant mucinous tumors of the ovary:Histologic criteria and clinical behavior. Cancer 1973;31:1031-1045

• 10) Chaitin BA, Gershenson DM, Evans HL:Mucinous tumors of the ovary:A clinicopathologic study of 70 cases. Cancer 1985;55:1958-1962

• 11) Hart WR:Ovarian epithelial tumors of borderline malignancy (Carcinomas of low malignant potential). Hum Pathol 1977;8:541-549

• 12) Young RH, Gilks CB, Scully RE:Mucinous tumors of the appendix associated with mucinous tumors of the ovary and pseudomyxoma peritonei. A clinicopathological analysis of 22 cases supporting an origin in the appendix. Am J Surg Pathol 1991;15:415-429

• 13) Suurmeijer AJH:Carcinosarcoma-like mural nodule in an ovarian mucinous tumour. Histopathology 1991;18:268-271

• 14) Russell P:Surface epithelial-stromal tumors of the ovary. Blaustein's Pathology of the Female Genital Tract (Kurman RJ, ed), 4th ed. 1994;pp755-762, Springer-Verlag, New York

• 15) Young RH, Scully RE:Oxyphilic clear cell carcinoma of the ovary. A report of nine cases. Am J Surg Pathol 1987;11:661-667

• 16) Roth L, Sternberg W:Proliferating Brenner tumors. Cancer 1971;27:687-693

• 17) Austin R, Norris H:Malignant Brenner tumor and transitional cell carcinoma of the ovary. A comparison. Int J Gynecol Pathol 1987;6:29-39

• 18) Silva EG, Tornos C, Bailey MA, et al:Undifferentiated carcinoma of the ovary. Arch Pathol Lab Med 1991;115:377-381

• 19) Young RH, Dickersin GR, Scully RE:Juvenile granulosa cell tumor of the ovary. A clinicopathological analysis of 125 cases. Am J Surg Pathol 1984;8:575-596

• 20) Nakashima N, Young RH, Scully RE:Androgenic granulosa cell tumors of the ovary. A clinicopathologic analysis of 17 cases and review of the literature. Arch Pathol Lab Med 1984;108:786-791

• 21) Stenwig JT, Hazekamp JT, Beecham JB:Granulosa cell tumors of the ovary. A clinicopathological study of 118 cases with long term follow-up. Gynecol Oncol 1979;7:136-152

• 22) Young RH, Scully RE:Ovarian sex cord-stromal tumors with bizarre nuclei. A clinicopathologic analysis of 17 cases. Int J Gynecol Pathol 1983;1:325-335

• 23) Nakamura S, Nakashima N, Ito M, et al:A case of ovarian granulosa cell tumor with invasive adenocarcinoma of the endometrium. A case report and review of the Japanese literature. Acta Pathol Jpn 1988;38(7):947-951

• 24) Zaloudek C, Norris HJ:Granulosa tumors of the ovary in children. A clinical and pathologic study of 32 cases. Am J Surg Pathol 1982;6:503-512

• 25) Meng N, Nakashima N, Nagasaka T, et al:Immunohistochemical characterization of extracellular matrix components of granulosa cell tumor of ovary. Pathol Int 1994;44:205-212

• 26) Prat J, Scully RE:Cellular fibromas and fibrosarcomas of the ovary. A comparative clinicopathologic analysis of seventeen cases. Cancer 1981;46:2663-2670

• 27) Ramzy I:Signet-ring stromal tumor of ovary. Histochemical, light, and electron microscopic study. Cancer 1976;38:166-172

• 28) Dickersin GR, Young RH, Scully RE:Signet-ring stromal and related tumors of the ovary. Ultrastruct Pathol 1995;19:401-419

• 29) Young RH, Scully RE:Endocrine tumors of the ovary. Current Topics in Pathology, Gynecological Tumors. Recent Progress in Diagnostic Pathology (Sasano N, ed). 1992;pp113-164, Springer-Verlag, Berlin, Heiderberg

• 30) Young RH, Scully RE:Ovarian Sertoli-Leydig cell tumors. A clinicopathological analysis of 207 cases. Am J Surg Pathol 1985;9:543-569

• 31) Scully RE:Sex cord-stromal, steroid cell, and germ cell tumors of the ovary. Gynecology and Obstetrics (Sciarra JJ, ed). 1995;pp1-24, Lippincott, Philadelphia

• 32) Young RH, Perez-Atayde AR, Scully RE:Ovarian Sertoli-Leydig cell tumor with retiform and heterologous components. Report of a case with hepatocytic differentiation and elevated serum alpha-fetoprotein. Am J Surg Pathol 1984;8:709-718

• 33) Young RH, Scully RE:Ovarian Sertoli-Leydig cell tumors with a retiform pattern. A problem in histopathologic diagnosis. A report of 25 cases. Am J Surg Pathol 1983;7:755-771

• 34) Young RH, Prat J, Scully RE:Ovarian Sertoli-Leydig cell tumors with heterologous elements I. Gastrointestinal epithelium and carcinoid. A clinicopathologic analysis of thirty-six cases. Cancer 1982;50:2448-2456

• 35) Prat J, Young RH, Scully RE:Ovarian Sertoli-Leydig cell tumors with heterologous elements II. Cartilage and skeletal muscle. A clinicopathological analysis of twelve cases. Cancer 1982;50:2465-2475

• 36) Scully RE:Sex cord tumor with annular tubules. A distinctive ovarian tumor of the Peutz-Jeghers syndrome. Cancer 1970;25:1107-1121

• 37) Young RH, Welch WR, Dickers in GR, et al:Ovarian sex cord tumor with annular tubules. Review of 74 cases including 27 with Peutz-Jeghers syndrome and four with adenoma malignum of the cervix. Cancer 1982;50:1384-1402

• 38) Young RH, Scully RE:Ovarian steroid cell tumors associated with Cushing's syndrome. A repot of three cases. Int J Gynecol Pathol 1987;6:40-48

• 39) Hayes MC, Scully RE:Ovarian steroid cell tumor (not otherwise specified). A clinicopathological analysis of 63 cases. Am J Surg Pathol 1987;11:835-845
  pubmed

• 40) Pressley RH, Muntz HG, Falkenberry S, et al:Serum lactic dehydrogenase as a tumor marker in dysgerminoma. Gynecol Oncol 1992;44:281-283

• 41) Stewart CJR, Farquharson MA, Foulis AK:Characterization of the inflammatory infiltrate in ovarian dysgerminoma:An immunocytochemical study. Histopathology 1992;20:491-497

• 42) Zaloudek CJ, Tavassoli FA, Norris HJ:Dysgerminoma with syncytiotrophoblastic giant cells. A histologically and clinically distinctive subtype of dysgerminoma. Am J Surg Pathol 1981;5:361-367

• 43) Talerman A:Germ cell tumor of the ovary, Blaustein's Pathology of the Female Genital Tract (Kurman RJ, ed). 1994;pp851-859, Springer-Verlag, New York

• 44) Teilum G:Endodermal sinus tumors of the ovary and testis. Comparative morphogenesis of the so-called mesonephroma ovarii (Schiller) and extraembryonic (yolk sac-allantoic) structures of the rat's placenta. Cancer 1959;12:1092-1104

• 45) Kurman RJ, Norris HJ:Endodermal sinus tumor of the ovary. A clinical and pathologic analysis of 71 cases. Cancer 1976;38:2404-2419

• 46) Kawai M, Furuhashi Y, Kano T, et al:Alpha-fetoprotein in malignant germ cell tumors of the ovary. Gynecol Oncol 1990;39:160-166

• 47) Teilum G:Special Tumors of Ovary and Testis. Comparative Pathology and Histological Identification. 1976;pp33-50, Munksgaard, Copenhagen

• 48) Nakashima N, Murakami S, Fukatsu T, et al:Characteristics of "embryoid body" in human gonadal germ cell tumors. Hum Pathol 1988;19:1144-1154

• 49) Nakashima N, Fukatsu T, Nagasaka T, et al:The frequency and histology of hepatic tissue in germ cell tumors. Am J Surg Pathol 1987;11:682-692

• 50) Prat J, Bhan AK, Dickersin GR, et al:Hepatoid yolk sac tumor of the ovary (endodermal sinus tumor with hepatoid differentiation). A light microscopic, ultrastructural and immunohistochemical study of seven cases. Cancer 1982;50:2355-2368

• 51) Ulbright TM, Roth LM, Brodhecker CA:Yolk sac difrerentiation in germ cell tumors. A morphologic study of 50 cases with emphasis on hepatic, enteric, and parietal yolk sac features. Am J Surg Pathol 1986;10:151-164

• 52) Nogales FF Jr, Matilla A, Nogales-Ortiz F, et al:Yolk sac tumors with pure and mixed polyvesicular vitelline pattern. Hum Pathol 1978;9:553-556

• 53) Cohen MB, Friend DS, Molnar JJ, et al:Gonadal endodermal sinus (yolk sac) tumor with pure intestine differentiation:A new histologic type. Pathol Res Pract 1987;182:609-616

• 54) Clement PB, Young RH, Scully RE:Endometrioid-like variant of ovarian yolk sac tumor. A clinicopathological analysis of eight cases. Am J Surg Pathol 1987;11:767-778

• 55) Kurman RJ, Norris HJ:Embryonal carcinoma of the ovary. A clicopathologic entity distinct from endodermal sinus tumor resembling embryonal carcinoma of the adult testis. Cancer 1976;38:2420-2433

• 56) Axe SR, Klein VR, Woodruff JD:Choriocarcinoma of the ovary. Obstet Gynecol 1985;66:111-114

• 57) Linder D, McCaw BK, Hecht F:Parthenogenic origin of benign ovarian teratomas. N Engl J Med 1975;292:63-66

• 58) Koulos JP, Hoffman JS, Steinhoff MM:Immature teratoma of the ovary. Gynecol Oncol 1989;34:46-49

• 59) Norris HJ, Zirkin HJ, Benson WL:Immature (malignant) teratoma of the ovary. A clinical and pathologic study of 58 cases. Cancer 1976;37:2359-2372

• 60) O'Connor DM, Norris HJ:The reproducibility of grading ovarian immature teratomas. Mod Pathol 1993;6:77A

• 61) Ihara T, Ohara K, Satoh H et al:Histological grade and karyotype of immature teratoma of the ovary. Cancer 1984;54:2988-2994

• 62) Hirakawa T, Tsuneyoshi M, Enjoji M:Squamous cell carcinoma arising in mature cystic teratoma of the ovary. Clinicopathologic and topographic analysis. Am J Surg Pathol 1989;13:397-405

• 63) Devaney K, Snyder R, Norris HJ, et al:Proliferative and histologically malignant struma ovarii:A clinicopathologic study of 54 cases. Int J Gynecol Pathol 1993;12:333-343

• 64) Robboy SJ, Norris HJ, Scully RE:Insular carcinoid primary in the ovary. A clinicopathologic analysis of 48 cases. Cancer 1975;36:404-418

• 65) Robboy SJ, Scully RE, Norris HJ:Primary trabecular carcinoid of the ovary. Obstet Gynecol 1977;49:202-207

• 66) Motoyama T, Katayama Y, Watanabe H, et al:Functioning ovarian carcinoids induced severe constipation. Cancer 1992;70:513-518

• 67) Alenghat E, Okagaki T, Talerman A:Primary mucinous carcinoid tumor of the ovary. Cancer 1986;58:777-783

• 68) Matias-Guiu X, Forteza J, Prat J:Mixed strumal and mucinous carcinoid tumor of the ovary. Int J Gynecol Pathol 1995;14:179-183

• 69) Wolpert HR, Fuller AF, Bell DA:Primary mucinous carcinoid tumor of the ovary. A case report. Int J Gynecol Pathol 1989;8:156-162

• 70) Aguirre P, Scully RE:Malignant neuroectodermal tumor of the ovary, a distinctive form of monodermal teratoma. Report of five cases. Am J Surg Pathol 1982;6:283-292

• 71) Kleinman GM, Young RH, Scully RE:Primary ovarian neuroectodermal tumors. A report of 25 cases. Am J Surg Pathol 1993;17:764-778

• 72) Papadopoulos AJ, Ahmed H, Pakarian FB, et al:Sebaceous carcinoma arising within an ovarian cystic mature teratoma. Int J Gynecol Cancer 1995;5:76-79

• 73) Scully RE:Gonadoblastoma. A gonadal tumor related to the dysgerminoma (seminoma) and capable of sex-hormone production. Cancer 1953;6:455-463

• 74) Obata NH, Nakashima N, Kawai M, et al:Case report. Gonadoblastoma with dysgerminoma in one ovary and gonadoblastoma with dysgerminoma and yolk sac tumor in the contralateral ovary in a girl with 46XX karyotype. Gynecol Oncol 1995;58:124-128

• 75) Nakashima N, Nagasaka T, Fukata S, et al:Ovarian gonadoblastoma with dysgerminoma in a woman with two normal children. Hum Pathol 1989;20:814-816

• 76) Talerman A:A distinctive gonadal neoplasm related to gonadoblastoma. Cancer 1972;30:1219-1224

• 77) Young RH, Oliva E, Scully RE:Small cell carcinoma of the ovary, hypercalcemic type. A clinicopathologic analysis of 150 cases. Am J Surg Pathol 1994;18:1102-1116

• 78) Eichhorn JH, Young RH, Scully RE:Primary ovarian small cell carcinoma of pulmonary type. A clinicopathologic, immunohistologic and flow cytometric analysis of 11 cases. Am J Surg Pathol 1992;16:926-938

• 79) Ishikura H, Scully RE:Hepatoid carcinoma of the ovary. A newly described tumor. Cancer 1987;60:2775-2784

• 80) Matsuda M, Ishikura H, Murakami K, et al:Hepatoid carcinoma of the ovary:A case report. Int J Gynecol Pathol 1991;10:302-310

P.162 掲載の参考文献

• 1) Sekiguchi I, Suzuki M, Tamada T:Estrogen producing activity in epithelial ovarian tumors and dermoid cyst. Asia-Oceania J Obstet Gynaecol 1989;15:367-374

• 2) 山片重房, 山本久美夫, 山本啓司, ほか:上皮性卵巣腫瘍のエストロゲン産生能に関する研究. 日本産科婦人科学会雑誌1989;41:1761-1768

• 3) Scully RE, Cohen RE:Oxidative-enzyme activity in normal and pathologic human ovaries. Obstet Gynecol 1964;24:667-681

• 4) Turen A:Hormonal secretion of Krukenberg tumors. Acta Endocrinol 1955;20:50-56

• 5) Kitazawa R, Kitazawa S, Matsui T, et al:In situ detection of parathyroid hormone-related protein in ovarian clear cell carcinoma. Hum Pathol 1997;28:379-382

• 6) 鈴木 瞭, 東條伸平:ホルモン産生腫瘍の診断法-ステロイドホルモン産生腫瘍を中心として. 産婦人科MOOK 28, 卵巣腫瘍(坂元正一, 滝 一郎, 室岡 一, 編). 1984;pp154-170, 金原出版, 東京

• 7) Motoyama T, Katayama Y, Watanabe H, et al:Functioning ovarian carcinoids induce severe constipation. Cancer 1992;70:513-518

• 8) Broadus AE, Mangin M, Ikeda K, et al:Humoral hypercalcemia of cancer:Identification of a novel parathyroid hormone like peptide. N Engl J Med 1988;319:556-563

• 9) Fujino T, Watanabe T, Yamaguchi K, et al:The development or hypercalcemia in a patient with an ovarian tumor producing parathyroid hormone-related protein. Cancer 1992;70:2845-2850
  pubmed

• 10) Barrenetxea G, Schneider J, Centeno MM, et al:Pure theca cell tumors. A clinicopathologic study of 29 cases. Eur J Gynaecol Oncol 1990;11:429-432

• 11) Scully RE:Sex-cord tumor of the ovary. Pathology of the Female Genital Tract (Blaustein A, ed). 1982;pp581-601, Springer Verlag, New York

• 12) Stenwig JT, Hazekamp JT, Beecham JB:A clinicopathological study of 118 cases with long-term follow up. Gynecol Oncol 1979;7:136-1521

• 13) Anikwue C, Dawood MY, Kramer E:Granulosa and theca cell tumors. Obstet Gynecol 1978;51:214-220

• 14) 井浦俊彦, 伊藤正孝, 藤井亮太, ほか:悪性卵巣腫瘍のホルモン産生. 産婦人科の実際19941 43:1409-1413

• 15) Bonaventura LM, Judd H, Roth LM, et al:Androgen. estrogen and progestogen production by a lipid cell tumor of the ovary. Am J Obstet Gynecol 1978;131:403-409

• 16) Scully RE:Tumor of the ovary and maldeveloped gonads. 1979, AFIP, Washington DC

• 17) 高倉賢二, 岡村 均, 麻生武志, ほか:卵巣男化腫瘍の形態学ならびに内分泌学的研究. 日本産科婦人科学会雑誌1981;33:961-968

• 18) Jeppsson S, Karlsson S, Kullander S:Gonadal steroids, gonadotropins and endometrial histology in postmenopausal women with malignant ovarian tumors. Acta Obstet Gynecol Scand 1986;65:207-210

• 19) 小林三津子, 北山俊也, 矢本希夫, ほか:上皮性卵巣腫瘍の性ステロイド産生能. 産科と婦人科 1993;60:1357-1361

• 20) Muecher EK:Testosterone-producing ovarian tumor associated with erythrocytosis, hyperuricemia, and recurrent deep vein thrombosis. Am J Obstet Gynecol 1977;129:467-469

• 21) Casthely S, Diamandis HP, Pierre-Louis LR:Hilar cell tumor of the ovary:Diagnostic value of plasma testosterone by selective ovarian vein catheterization. Am J Obstet Gynecol 1977;129:108-110

• 22) Sasano H, Manson JL Sasaki E, et al:Immunohistochemical study of 3β-hydroxysteroid dehydrogenase in sex cord-stromal tumors of the ovary. Int J Gynecol Pathol 1990;9:352-362

• 23) Takayama K, Sasano H, Fukaya T, et al:Immunohistochemical localization of Ad4-binding protein with correlation to steroidgenic enzyme expression in cycling human ovaries and sex cord stromal tumors. J Clin Endocrinol Metab 1995;80:2815-2821

• 24) Rome RM, Fortune Dw, Quinn MA, et al:Functioning ovarian tumors in postmenopausal women. Obstet Gynecol 1981;57:705-710

• 25) Ramanath R, Slotman BJ:Endocrine factors in common epithelial ovarian cancer. Endocr Rev 1991;12:14-26

• 26) Heinonen PK, Tuimala R, Pyykko K:Peripheral venous concentration of oestrogens in postmenopausal women with ovarian cancer. Br J Obstet Gynaecol 1982;89:84-86

• 27) MacLusky NJ, Voit R, Lazo JS, et al:Aromatase activity in human ovarian cancer. Steroids 1987;50:423-433

• 28) Kaga K, Sasano H, Harada N, et al:Aromatase in human common epithelial ovarian neoplasms. Am J Pathol 1996;149:45-51

• 29) 清川貴子, 藍沢茂雄, 古里征国, ほか:上皮性卵巣腫瘍におけるホルモンと病理組織像. 日本臨床細胞学会雑誌 1995;34:140-144

• 30) Vesterinen E, Purola E, Wahlstrom T:Oestrogenic activity associated with ovarian cystadenomas after the menopause. Ann Chir Gynaecol 1987;67:109-111

• 31) 山片重房, 山本久美夫, 松本義隆, ほか:卵巣腺癌細胞におけるエストロゲン産生. 日本産科婦人科学会雑誌1990;42:1703-1704

• 32) Sasano H, Suzuki T, Niikura H, et al:17β-hydroxysteroid dehydrogenase in common epithelial ovarian tumors. Mod Pathol 1996;9:386-391

• 33) Hughesdon PE:Thecal and allied reaction in ovarian tumors. J Obstet Gynaecol Br Commonw 1956;65:702-709

• 34) Bjorkholm E, Silversward G:Prognostic factors in granulosa-cell tumors. Gynecol Oncol 1981;11:261-274

• 35) Young RH, Dickerson GR, Scully RE:Juvenile granulosa cell tumor of the ovary. A clinicopathologic analysis of 125 cases. Am J Surg Pathol 1984;8:575-596

• 36) 滝 一郎, 上田外幸, 辻本正彦:性索・間質性腫瘍-診療のための婦人科腫瘍の臨床病理. 1992;pp208-226, メジカルビュー社, 東京

• 37) 日本産科婦人科学会, 日本病理学会, 編:卵巣腫瘍取扱い規約-第1部:組織分類およびカラーアトラス. 1990, 金原出版, 東京

• 38) Chalvardjian A, Scully RE:Sclerosing stromal tumors of the ovary. Cancer 1973;31:664-670

• 39) 篠原道興, 松浦祐介, 柏村正道:卵巣sclerosing stromal tumorの1例. 日本臨床細胞学会雑誌 1993;32:531-535

• 40) 古谷充子, 石倉 浩, 笹野公伸, ほか:卵巣の硬化性間質性腫瘍の免疫組織学的検討:そのホルモン産生能について. 日本産科婦人科学会雑誌1997;49:102-106

• 41) Tang M, Liu T:Ovarian sclerosing stromal tumors:Clinicopathologic study of 10 cases. Clin Med J 1982;95:186-190

• 42) Trimble C, Trimble EL, Hernandez E:Sertoli cell tumor. Tumor of the ovarian stroma. Clinical Gynecologic Pathology (Hernandez E, Atkinson BF, eds), 1st ed. 1995;pp501-525, WB Saunders, Philadelphia

• 43) Balsara G, Hernandez E:Luteoma of pregnancy. The ovary:Normal, physiologic changes, endometriosis, and metastatic tumors. Clinical Gynecologic Pathology (Hernandez E, Atkinson BF, eds), 1st ed. 1995;pp403-422, WB Saunders, Philadelphia

• 44) Young RH, Welch WR, Dickersin R, et al:Ovarian sex cord tumor with anular tubules:review of 74 cases including 27 with Peutz-Jeghers syndrome and four with adenoma malignum of the cervix. Cancer 1982;50:1384-1402

• 45) Hart WR, Kurman N, Crissmann JD:Ovarian neoplasm resembling sex cord tumors with annular tubules. Cancer 1980;45:2352-2363

• 46) 半藤 保, 塩田敦子:ホルモン産生卵巣腫瘍の組織学的特徴. 病理と臨床1990;8:1249-1255

• 47) Chalvardjian A, Derzko C:Gynandroblastoma:Its ultrastructure. Cancer 1982;50:710-721

P.179 掲載の参考文献

• 1) Novak's Gynecology, 12th ed (Berek JS, ed). 1996, pp1212-1214, Williams & Wilkins. Baltimore

• 2) Krukenberg F:Uber das Fibrosarcoma ovarii mucocellulare (carcinomatodes). Arch Gynaekol 1895;50;287-321

• 3) Descriptive catalogue of the pathological specimens contained in the Museum of the Royal College of Surgeons of England. 1846

• 4) Waldeyer R:Die Entwickelung der Carcinome. Virchows Arch Path Anat 1892;55:67-159

• 5) Welch O:Diffuse infiltrating carcinoma of the stomach. Bull Johns Hosp 1893;4:98-99

• 6) Kraus E:Ueber das Zustandekommen der Krebsmetastasen im varium bei primarem Krebseines anderen Bauch organs. Mschr Geburtsch Gynak 1901;14:1-30

• 7) Schlagenhaufer F:Uber das metastatische Ovarialcarcinom nach Krebs des Magens. Geburtsch Gynak 1902;15:485-528

• 8) Glockner A:Uber secundares Ovariacarcinom. Arch Gynak 1904;72:410-469

• 9) Novak E, Gray LA:Krukenberg tumors of the ovary. Clinical and pathological study of 21 cases. Surg Gynecol Obstet 1938;66:157-165

• 10) Woodruff JD, Novak ER:The Krukenberg tumor. Study of 48 cases from the ovarian tumors registry. Obstet Gynecol 1960;15:351-360

• 11) Hertig AT, Gore H:The C. V. Pathology, 5th ed. 1966;pp1183-1184, Mosby, S Louis

• 12) 渡部 洋, 野田起一郎:Krukenberg腫瘍の近況. 産科と婦人科1988;55(4):881-884

• 13) 日本産婦人科学会, 日本病理学会, 編:卵巣腫瘍取扱い規約-第1部:組織分類ならびにカラーアトラス. 1990;pp43-44, 金原出版, 東京

• 14) 山辺 徹, 中山正博:Krukenberg腫瘍に関する臨床病理. 産科と婦人科1972;39:1155-1162

• 15) 日本産科婦人科学会婦人科腫瘍委員会:全国卵巣悪性腫瘍調査成績, 第2報. 1972

• 16) 樋口一成, 加藤 俊, 小川重男, ほか:卵巣充実性腫瘍. 日本産婦人科全書13巻. 1964;金原出版, 東京

• 17) 蔵本博行, 脇田邦夫, 上坊敏子, ほか:Krukenberg腫瘍の臨床病理学的検討. 産科と婦人科 1982;49:228-232

• 18) 薬師寺道明, 田崎民和, 西村治夫, ほか:Krukenberg tumors of the ovary:A clinicopathologic analysis of 112 cases. Acta Obstet Gynaecol Jpn 1987;39:479-485

• 19) Diddle A:Krukenberg tumors:Diagnostic problem. Cancer 1955;8:1026
  pubmed

• 20) 吉成哲夫, 井上和彦, 野沢定俊, ほか:Krukenberg氏腫瘍の2例. 東北医学雑誌1959;60:641-644

• 21) Gagnon Y, Tetu B:Ovarian metastasis of breast carcinoma:A clinicopathologic study of 59 cases. Cancer 1989;64:892-898

• 22) 槇 哲夫, 間島 進, 吉田弘一, ほか:転移の臓器特性-胃癌. 癌の臨床1967;13:208-217

• 23) 星野智雄, 久野敬二郎:癌研外科におけるKrukenberg腫瘍. 癌の臨床1964;10:892

• 24) 佐藤有規, 中島聡, 西満正, ほか:Krukenberg腫瘍21例の検討. Oncologia 1988;21:122-127

• 25) 新本 稔, 吉中 建, 弘野正司, ほか:胃癌卵巣転移の臨床病理学的検討. 消化器外科1984;7:1895-1900

• 26) 清水 廣, 山崎正人, 熊谷正俊, ほか:Krukenberg 腫瘍の術前診断-特に臨床的背景と画像診断について. 産婦人科の実際1989;38:1473-1478

• 27) von Virieux C:Untersuchungen uber Haufigkeit und Entstehungsweise von Krebsmetastasen in den Eierstecken. Gynaecologia 1962;153:209-224

• 28) Karsh J:Secondary malignant disease of the ovaries. Am J Obstet Gynecol 1951;61:154-160

• 29) 藤原恵一, 大石雄二, 小池浩文, ほか:原発性, 転移性の鑑別が困難であった症例検討および剖検例の臨床病理学的解析と文献的考察. 日本婦人科病理・コルポスコピー学会雑誌1994;12(2):161-166

• 30) 日本病理学会, 編:日本病理剖検輯報. 1993-1997

• 31) 森脇昭介, 高嶋成光, 北島武志, ほか:転移性卵巣腫瘍-剖検例と手術例の比較. 癌の臨床 1981;27:343-347

• 32) 宮下博躬:胃癌の卵巣転移に関する研究. 日本癌治療学会誌1969;4:469-481

• 33) 長廻 紘, 竹本忠良, 岩塚廸雄, ほか:Krukenberg腫瘍として発見された小さな早期胃癌IIcの1例. 臨床外科1970;25:989-993

• 34) 渡辺騏七郎, 石川為信, 川中 剛, ほか:胃原発生Krukenberg腫瘍について. 医療1977;31 (増刊号):212

• 35) 佐島敬清, 赤塚祝子, 山内嘉夫, ほか:Krukenberg腫瘍を呈したIIc期早期胃癌の1例. Prog Dig En dos 1977;10:217

• 36) 熊谷一秀, 屋良昭彦, 滝沢直樹, ほか:表層拡大型胃癌にみられた卵巣転移の1例. Prog Dig En dos 1981;20:218

• 37) 矢野健次, 高橋 信, 表原多文, ほか:粘膜内胃癌の頸部リンパ節, 両側卵巣, 骨, 髄膜転移をきたした1例. 広島医学1989;42(11):1714-1716

• 38) 秋本亮一, 溝渕 昇, 土谷昇二, ほか:広汎な転移を伴った早期胃癌の1例. 日本消化器外科学会雑誌1991;24:103-107

• 39) 安田雅弘, 五十嵐裕一, 吉谷徳夫, ほか:IIc型の早期胃癌由来の転移性卵巣腫瘍(Krukenberg 腫瘍)の1例. 産科と婦人科1993;60:877-880

• 40) 西田 敬:転移性卵巣癌の臨床. 日本婦人科病理・コルポスコピー学会雑誌1994;12(2):167-171

• 41) 田村俊男, 金井督之, 上坊敏子, 蔵本博行:消化器症状を伴わずに癌性胸水貯留, 卵巣を含む全身転移を来した胃癌の1例. 日本臨床細胞学会神奈川支部会誌1997;2:71-75

• 42) 清川貴子, 佐々木寛, 磯西成治, ほか:転移性卵巣癌の臨床-その予後因子と臨床的問題. 日本婦人科病理・コルポスコピー学会雑誌1994;12(2):155-160

• 43) Petru E, Pickel H, Hevdarfadai M, et al:Nongenital cancers metastatic to the ovary. Gynecol Oncol 1992;44:83-86

• 44) 松本智恵子, 雨宮良彦, 遠藤 健, ほか:原発巣が生前同定されなかった転移性卵巣腫瘍の一例. 日本産科婦人科学会東京地方部会会誌1994;43(4):481-485

• 45) 森沢孝行, 脇田邦夫, 上坊敏子, ほか:原発巣の診断が困難であったKrukenberg 腫瘍の一例. 日本産科婦人科学会神奈川地方部会会誌1982;18(2):106-111

• 46) 岩永 剛, ほか:妊娠・分娩の胃癌に及ぼす影響. 消化器外科セミナー14. 1984;p105, へるす出版, 東京

• 47) 辻 靖, ほか:免疫染色でエストロゲン・レセプター陽性を認めた若年女性胃癌の2症例. 旭川赤十字病院医学雑誌1992;6:110

• 48) 堀 雅晴, 高木国夫, 西 満正, ほか:胃癌のエストローゲン, プロゲステロンリセプターに対する検討. Oncologia 1986;19:21-26

• 49) 小川朋子, 東 俊策, 岡田喜克, ほか:Krukenberg腫瘍を伴った妊娠合併胃癌の1例. 外科 1997;59:1391-1393

• 50) 薬師寺道明, 田崎民和:転移性卵巣腫瘍-Krukenberg 腫瘍. 病理と臨床1990;8(10):1261-1266

• 51) 安達 進, 野田恒夫, 伊藤公彦, ほか:Second-look operationの成績からみたCDDP腹腔内投与の有用性. 日本癌治療学会誌1993;28(10):1731-1737

• 52) Israel SL, Helsel EV Jr, Hausman DH:The challenge of metastatic ovarian carcinoma. Am J Obstet Gynecol 1965;93:1094-1101

• 53) Webb M, Decker D, Mussy E:Cancer metastatic to the ovary. Obstet Gynecol 1975;45:391-396

• 54) 井浦俊彦, 高林晴夫, 桑原惣隆, ほか:卵巣癌に対するCAP療法による治療効果-DNA ploidyによる検討. Oncol chemother 1993;9(3):259-267

• 55) Didolkar MS, Fanous N, Elias EG, et al:Metastatic carcinomas from occult primary tumors:A study of 254 patients. Ann Surg 1977;186:625-630

• 56) 加藤 拓, 高橋久雄, 渡辺義二, ほか:胃癌術中腹腔内洗浄細胞診の検討. 日本臨床細胞学会雑誌1992;31(6):925-930

• 57) 頼 建光, 坂本尚登, 伏見清秀, ほか:液性因子と水・電解質異常-転移性卵巣腫瘍に伴った高Ca血症とPTHrP, TNF-α, およびIL-6の関連について. 臨床体液1993;20(1):59-65

• 58) 深澤洋幸, 岡本美枝, 成島正昭, ほか:汎発性血管内凝固症候群と肺血栓塞栓症を合併した転移性卵巣癌の1例. 産婦人科の実際1993;42(10):1665-1668

• 59) 古里征國, 原田 徹, 鷹橋浩幸, ほか:転移性卵巣癌の臨床病理学的問題点. 日本婦人科病理・コルポスコピー学会雑誌1994;12(2):152-154

• 60) 玉井 修, 富野秀司, 野里栄治, ほか:消化器癌の卵巣転移巣におけるケラチン7及びケラチン20の染色性の検討. 消化器癌の発生と進展1997;9:363-366

• 61) Duarte I, Lianos O:Patterns of metastases in intestinal and difruse types of carcinoma of the stomach. Hum Pathol 1981;12:237-242

• 62) 本山悌一:転移性卵巣癌の臨床と病理-臨床の立場から. 日本婦人科病理・コルポスコピー学会雑誌1994;12(2):146-151

• 63) 田崎民和, 西村治夫, 薬師寺道明, ほか:Krukenberg腫瘍の卵巣初期転移巣における病理組織学的検討. 日本産科婦人科学会雑誌1990;42:353-359

• 64) 三輪晃一, 菅原昇次郎, 松木伸夫, ほか:胃癌の卵巣転移. 消化器外科1984;7:1571-1575

• 65) 落合正宏, 今津浩喜, 船曳孝彦, ほか:両側卵巣転移術後に発見された早期胃癌の1例. 日本消化器外科学会雑誌1992;25:2794-2798

• 66) 田崎民和, 西村治夫, 薬師寺道明, ほか:Krukenberg腫瘍の間質増生機序に関する組織学的検討. 久留米医学会雑誌1985;48:21-36

• 67) 森脇昭介, 春間 賢, 高嶋成光, ほか:潜在性卵巣腫瘍-転移性腫瘍. 癌の臨床1979;25:1400 1406

• 68) 胃癌研究会, 編:胃癌取扱い規約, 第13版. 1999;金原出版, 東京

• 69) 操 厚, 佐藤昭夫, 伊藤隆夫, ほか:早期胃癌症例の検討-とくにリンパ節転移例を中心に. 癌の臨床1982;28:1132-1136

• 70) 石井俊世, 三浦敏夫, 原田達郎, ほか:教室における早期胃癌手術症例の検討-特にリンパ節転移を中心にして. 日本消化器外科学会雑誌1981;14:39-44

• 71) 曽和融生, 加藤保之, 向井隆一郎, ほか:早期胃癌の臨床病理組織学的検討-とくに肉眼形態とリンパ節転移について. 外科治療1983;48:274-283

• 72) 栗山 洋, 東 弘, 宮本徳廣, ほか:胃癌におけるリンパ節侵襲の検討-とくに早期胃癌について. 日本消化器外科学会雑誌1982;15:1314-1317

• 73) 高橋俊雄, 河野研一, 山口俊晴, ほか:早期胃癌(A, AM, M 領域癌). 日本消化器外科学会雑誌1983;16:123-126

• 74) 山田栄吉, 紀藤 毅, 鈴木 亮, ほか:早期胃癌の予後. 外科1979;41:346-454

• 75) 岩永 剛, 古河洋, 神前五郎, ほか:早期胃癌の進展, 再発様式よりみた手術法. 手術 1981;18:295

• 76) 貝原信明, 出村英明, 古賀成昌, ほか:早期胃癌術後死亡原因の分析. 胃と腸1984;19(7):739-743

• 77) 鈴木博孝, 遠藤光夫, 鈴木 茂, ほか:早期胃癌におけるリンパ節転移の検討. 日本消化器外科学会雑誌1984;17(8):1517-1526

• 78) 長谷川明広, 渡辺祐実, 吉野直樹, ほか:乳腺原発転移性卵巣癌の1例. 産婦人科の実際 1995;44:269-272

• 79) 坂本吾偉, 菅野晴夫, Hartman WH:日米乳癌の臨床病理学的比較研究. 癌の臨床1979;25:161-170

• 80) Lee YTN, Hori JM:Significance of ovarian metastasis in therapeutic oophorectomy for advanced breast cancer. Cancer 1971;27:1374-1378

• 81) Harris M, Howell A, Chrissohou M:A comparison of the metastatic pattern of infiltrating lobular carcinoma and infiltrating duct carcinoma of the breast. Br J Cancer 1984;50:23-30

• 82) 長谷川明広, 渡辺祐実, 吉野直樹, ほか:転移性卵巣癌の臨床的検討. 島根県立中央病院医学雑誌1994;21(1):22-26

• 83) 田中 隆, 森本忠興, 駒木幹正, ほか:乳腺小葉癌の臨床的検討. 癌の臨床1987;33:1309-1313

• 84) 山口俊昌, 裏川公章, 中本光晴, ほか:卵巣転移大腸癌の4例. 日本消化器外科学会雑誌 1989;22:2882-2885

• 85) 藤吉 学, 礒本浩晴, 白水和雄, ほか:大腸癌の卵巣転移に関する検討. 日本消化器外科学会雑誌1989;22:1116-1120

• 86) 佐藤輝彦, 鎌野俊紀, 内田紀之, ほか:大腸癌の卵巣転移に関する臨床的研究. 日本大腸肛門病学会雑誌1990;43:56-60

• 87) Grafrner HOL, Alm PO, Oscarson JE:Prophylactic oohorectomy in colorectal carcinoma. Am J Surg 1983;146:233-235

• 88) MacKeigan JM, Ferguson JA:Prophylactic oophorectomy and colorectal cancer in premenopausal patients. Dis Colon Rectum 1979;22:401-405

• 89) 勝美正治, 田伏克惇, 江川 博, ほか:大腸癌手術後まもなく発生した転移性卵巣腫瘍. 消化器外科1985;8:86-88

• 90) Abrams HL, Spiro R, Goldstein N:Metastases in carcinoma. Cancer 1950;3:74-85

• 91) 田代和弘, 日高久光, 樋口隆一, ほか:大腸癌治癒切除後の卵巣転移に関する臨床病理学的検討. 日本大腸肛門病学会雑誌1995;481156-161

• 92) Birnkrant A, Sampson J, Sugarbaker PH:Ovarian metastasis from colorectal cancer. Dis Colon Rectum 1986;29:767-771

• 93) Perdomo JA, Hizuta A, Iwagaki H, et al:Ovarian metastasis in patients with colorectal carcinoma. Acta Med Okayama 1994;48:43-46

• 94) Mason MH, Kovalcik PJ:Ovarian metastases from colon carcinoma. J Surg Oncol 1981;17:33-38

• 95) 佐々木寛, 清川貴子, 寺島芳輝, ほか:転移性卵巣癌の予後因子. 日本外科系連合学会誌 1994;19(1):65-70

• 96) 田中 実, 中野昌志, 奥 雅志, ほか:直腸癌治癒切除後両側卵巣転移で再発した例. 日本大腸肛門病学会誌1992;45:475-479

• 97) 富永 博, 舘林欣一郎, 年光昌宏, ほか:大腸癌の卵巣転移7症例. 日本臨床外科医学会雑誌 1983;44:237

• 98) 野村則和, 岩井昭彦, 武田佳彦, ほか:大腸癌転移性卵巣腫瘍の1例. 日本臨床外科医学会雑誌1997;58:2429-2433

• 99) Beger A:Ein Fall von Krebs des Wurmfortsatzes. Berl Ktin Wscr 1882;19:616-618

• 100) 川上和彦, 馬場正三, 荻原裕之, ほか:絨毛発育を内視鏡的に認めた虫垂絨毛癌の1例. 胃と腸1990;25:1227-1230

• 101) 桐山正人, 山口明夫, 大山繁和, ほか:原発性虫垂癌の2例. 消化器外科1986;93:1169-1172

• 102) 久米田茂喜, 町田恵美, 小出直彦, ほか:原発性虫垂癌症例の検討. 医療1996;50:139-143

• 103) 河野良寛, 木村秀幸, 片岡和男, ほか:原発性虫垂癌の13例. 臨床外科1982;37:1601-1604

• 104) 梶原博一, 小泉博義, 熊本吉一, ほか:原発性虫垂癌の3例. 横浜医学1984;35:9-15

• 105) 森崎 隆, 佐藤 裕, 岸川英樹, ほか:原発性虫垂癌の1例-本邦報告例の検討. 外科1987;49:750-753

• 106) 植野りえ, 寺岡文敏, 豊岡理恵子, ほか:虫垂原発転移性卵巣癌に対する治療経験-特に手術療法と術後化学療法に関して. 日本産科婦人科学会東京地方部会会誌1997;46:238-241

• 107) Hirschfield LS, Kahn LB, Winkler B, et al:Adenocarcinoid of the appendix presenting as bilateral Krukenberg's tumor of the ovaries. Arch Pathol Lab Med 1985;109:930-933

• 108) 早川 智, 千島史尚, 土岐政嗣, ほか:転移性卵巣腫瘍として発見された虫垂原発adenocar-cinoidの1症例. 日本産科婦人科学会神奈川地方部会会誌1988;24:173-175

• 109) Sanders RJ, Axtell HK:Carcinoids of the gastrointestinal tract. Surg Gynecolobstet 1964;119:369-380

• 110) Subbuswamy SG, Gibbs NM, Ross CF, et al:Goblet cell carcinoid of appendix. Cancer 1974;34:338-344

• 111) Warkel RL, Cooper PH, Helwig EB:Adenocarcinoid, a mucin-producing carcinoid tumor of the appendix:a study of 39 cases. Cancer 1978;42:2781-2793

• 112) Chu JY, Carddock TV, Danis RK, et al:Ovarian tumor as manifestation of relapse in acute lymphoblastic leukemia. Cancer 1981;48:377-379

• 113) 小島 瑞:腫瘤形成性白血病. 日本血液学会雑誌1963;26:62-68

• 114) 栗田宗次:腫瘤形成性白血病について. 臨床血液1982;23:443-440

• 115) Wheelock MC Putong P:Ovarian metastases from adenocarcinomas of colon and rectum. Obstet Gynecol 1959;14:291-295

P.193 掲載の参考文献

• 1) Kottmeier HL:Presentation of therapeutic results in carcinoma of the female pelvis:Experience of the Annual Report on the Results of Treatment in Carcinoma of the Uterus, Vagina, and Ovary. Gynecol Oncol 1976;4:13-19

• 2) Kottmeier HL:Problems Relating to Classification and Stage-Grouping of Malignant Tumors in the Female Pelvis(The University of Texas MD Anderson Hospital and Tumor Institute), 1969;pp17-32, Year Book Medical, Chicago

• 3) FIGO News:Report presented by the Cancer Committee to the General Assembly of FIGO:New York, April, 1970. Int J Gynecol Obstet 1971;9:172-179

• 4) 上田外幸:臨床期別分類. 図説臨床癌シリーズ23, 卵巣腫瘍・睾丸腫瘍(末舛恵一, 加藤俊, 吉田修, 編). 1988;pp31-39, メジカルビュー社, 東京

• 5) 加藤 俊:卵巣腫瘍登録委員会報告. 日本産科婦人科学会雑誌1978;30:295-298

• 6) Announcement:Changes in definition of clinical staging for carcinoma of the cervix and ovary:International Federation of Gynecology and Obstetrics. Am J Obstet Gynecol 1987;156:263-264

• 7) 寺島芳輝, 落合和徳:卵巣腫瘍登録委員会報告-新臨床期別分類の提案について. 日本産科婦人科学会雑誌1988;40:121-122

• 8) FIGO News:Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynecol Obstet 1989;28:189-190

• 9) Serov SF, Scully RE, Sobin LH:Histological typing of ovarian tumours. International Histological Classification of Tumours, No 9. 1973, World Health Organization, Geneva

• 10) 日本産科婦人科学会, 日本病理学会, 編:卵巣腫瘍取扱い規約-第1部:組織分類ならびにカラーアトラス. 1990, 金原出版, 東京

• 11) Pecorelli S, Creasman WT, Petterson F, et al:FIGO Annual Report on the Results of Treatment in Gynaecological Cancer, twenty-third volume. Journal of Epidemiology and Biostatistics 1998;3:1-168

• 12) 日本産科婦人科学会, 編:卵巣腫瘍取扱い規約-第2部, 改訂第2版. 1997;pp3-5, 金原出版, 東京

• 13) 塚本直樹, 嘉村敏治, 松山敏剛, ほか:婦人科腫瘍に対するstaging laparotomy. 産婦人科治療 1990;60:121-127

• 14) Jadhon ME, Morgan MA, Kelsten ML, et al:Cytologic smears of peritoneal surfaces as a sampling technique in epithelial ovarian carcinoma. Obstet Gynecol 1990;75:102-105

• 15) Young RC, Decker DG, Wharton JT, et al:Staging laparotomy in early ovarian cancer. JAMA 1983;250:3072-3076

• 16) SGO Clinical Practice Guidelines:Management of Gynecologic Cancers. Society of Gynecologic Oncologists, Medical Practice and Ethics Committee. 1996, pp12-18, Chicago

P.200 掲載の参考文献

• 1) Rosenberg L, Shapiro S, Slone D, et al:Epithelial ovarian cancer and combination oral contraceptives. J Am Med Assoc 1982;247:3210-3212

• 2) La Vecchia C, Franceschi S, Decarli A:Oral contraceptive use and the risk of epithelial ovarian cancer. Br J Cancer 1984;50:31-34

• 3) The reduction in risk of ovarian cancer associated with oral-contraceptive use. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. N Engl J Med 1987;316:650-655

• 4) Epithelial ovarian cancer and combined oral contraceptives. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Epidemiol 1989;18:538-545

• 5) Adami HO, Bergstrom R, Persson I, et al:The incidence of ovarian cancer in Sweden, 1960-84. Am J Epidemiol 1990;132:446-452

• 6) Lew EA, Garfinkel L:Variations in mortality by weight among 750, OOO men and women. J Chron Dis 1979;32:563-576

• 7) Steinmetz KA, Potter JD:Vegetable, fruit, and cancer I:epidemiology. Cancer Cattses Control 1991;2:325-358

• 8) 大阪府環境保健部:大阪府におけるがん登録, 第57報. 1995;pp9-26

• 9) Parkin DM, Pisani P, Ferlay J:Estimates of the worldwide frequency of 16 major cancers in 1985. Int J Cancer 1993;54:594-606

• 10) La Vecchia C, Lucchini F, Negri E, et al:Trends of cancer mortality in Europe, 1955-1989:III breast and genital sitcs. Eur J Cancer 1992;28:927-998

• 11) Boyle P, La Vecchia C, Maisonneuve P, et al:Cancer epidemiology and prevention. Oxford Textbook of Oncology(Peckam MJ, Pinedo H, Veronesi U, eds). 1995;pp199-273. Oxford Medical Publications, Oxford

• 12) 山本嘉一郎:卵巣癌の化学療法. 産婦人科の進歩1997;49:17-23

• 13) Fleming ID, Cooper JS, Henson DE, et al. eds:AJCC Cancer Staging Manual. 1997. Lippincott, Philadelphia

• 14) International Union Against Cancer(UICC):TNM Classification of Malignant Tumours, 5th ed (Sobin LH, Wittekind Ch, eds). 1997. Wiley-Liss. New York

• 15) Boyle P, Leake RE:Ovarian cancer:Epidemiological and biological interactions. Ovarian Cancer 4. Proceedings of the Helene Harris symposium. May 1995(Sharp F, Blackett T, Leake R, et al, eds). 1996. Chapman & Hall Medical Publ. London

• 16) Pike MC:Age-related factors in cancers of the breast, ovary, and endometrium, J Chron Dis 1987;40 (suppl 2):595-695

• 17) 日本産科婦人科学会, 編:卵巣腫瘍取扱い規約, 第2部(改訂第2版). 1997;p7, 金原出版, 東京

• 18) Munnell EW, Tayler HC Jr:Ovarian carcinoma. A review of 200 primary and 51 secondary cases. Am J Obstet Gynecol 1949;58:943-959

• 19) Rubin P:A clitical analysis of current therapy of carcinoma of the ovary. Am J Roentgenol 1962;88:833-840

• 20) van Orden DE, McAllister WB, Zerne SR, et al:Ovarian carcinoma. The problem of staging and grading. Am J Obstet Gynecol 1966;94:195-202

• 21) Baak JP, Wisse-Brekelmans EC, Langley FA, et al:Morphometric data to FIGO stage and histological type and grade for prognosis of ovarian tumours. J Clin Pathol 1986;39:1340-1346

P.214 掲載の参考文献

• 1) 柏村正道:良性卵巣腫瘍. 図説産婦人科 VIEW 29, 画像診断(稲葉憲之, 寺島芳輝, 編). 1997;pp84-93, メジカルビュー社, 東京

• 2) 日本超音波医学会超音波診断基準に関する委員会:卵巣腫瘍のエコーパターン分類(案)公示について. 超音波医学1993;21(2):iii-v

• 3) Natori M, Saitoh M, Udagawa Y, et al:Evaluation of the echo-pattern classification of ovarian tumors as proposed by the Japan Society of Ultrasonics in Medicine:Its usefulness and reliability. Jpn J Med Ultrasonics 1995;22(7):3-7

• 4) 宇田川康博, 植嶋孝夫, 青木大輔, ほか:その他の糖鎖関連腫瘍マーカー. 図説産婦人科 VIEW 18, 腫瘍マーカー(加藤 紘, 野澤志朗, 編). 1995;pp134-143, メジカルビュー社, 東京

• 5) 宇田川康博, 植嶋孝夫, 進 伸幸, ほか:癌関連ガラクトース転移酵素(GAT). 臨床科学 1999;35(3):377-382

• 6) 宇田川康博, 斉藤美和, 野澤志朗:癌検診と腫瘍マーカー-CA602・CA546を用いた卵巣癌検診の試み. 臨床と研究1998;75(3):69-72

P.228 掲載の参考文献

• 1) NIH consensus conference:Ovarian cancer:Screening, treatment, and follow-up. NIH consensus development panel on ovarian cancer. JAMA 1995;273:491-497 (日本語版JAMA 1995年8月号に薬師寺道明訳が掲載されている)

• 2) Zanetta G, Chiari S, Rota S, et al:Conservative surgery for stage I ovarian carcinoma in women of childbearing age. Br J Obstet Gynaecol 1997;104(9):1030-1035

• 3) Einhorn LH, Williams SD, Donohue JP, et al:Cancer of the testes. Cancer-Principles and Practice of Oncology(DeVita VT, Hellman S, Rosenberg SA, eds), 2nd ed. 1985;pp986-990, Lippincott, Philadelphia (注:著者変更のため, 最新版(5th ed. 1997)には手術手技の図説は掲載されていない. Urol Clin North Am 1977;4:509-521も参照)

• 4) 恒松隆一郎:卵巣癌の手術. 癌の外科-手術手技シリーズ11, 婦人科癌(国立がんセンター, 編). 1994;pp78-84, メジカルビュー社, 東京

• 5) La Pianza A, Campani R, Dore R, et al:The clinical value of computed tomography and lymphography in detecting lymph node metastases from epithelial ovarian cancer. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1992;157:162-166

• 6) Petru E, Lahousen M, Tamussino K, et al:Lymphadenectomy in stage I ovarian cancer. Am J Obstet Gynecol 1994;170:656-662

• 7) Buchsbaum HJ, Brady MF, Miller A, et al:Surgical staging of carcinoma of the ovaries. Surg Gynecol Obstet 1989;169:226-232

• 8) Ahmed FY, Wilshaw E, A'Hern RP, et al:Natural history and prognosis of untreated stage I epithelial ovarian carcinoma. J Clin Oncol 1996;14:2968-2975

• 9) Veronesi U, Adamus J, Bandiera DC, et al:Inefficacy of immediate node dissection in stage I melanoma of the limbs. N Engl J Med 1977;297:627-630

• 10) McMasters KM, Giuliano AE, Ross MI, et al:Sentinel-lymph-node biopsy for breast cancer-not yet the standard of care. N Engl J Med 1998;339:990-995

• 11) Gynecologic Oncology Group Surgical Procedures Manual. 1994, Gynecologic Oncology Group Statistical Office, New York

• 12) Hoskins WJ:Epithelial ovarian carcinoma:Principles of primary surgery. Gynecol Oncol 1994;55:S91-S96

• 13) Young RC, Pecorelli S:Management of early ovarian cancer. Semin Oncol 1998;25:335-339

• 14) Tsuruchi N, Kamura T, Tsukamoto N, et al:Relationship between paraaortic lymph node involvement and intraperitoneal spread in patients with ovarian cancer-A multivariate analysis. Gynecol Oncol 1993;49:51-55

• 15) Onda T, Yoshikawa H, Yokota H, et al:Assessment of metastases to aortic and pelvic lymph nodes in epithelial ovarian carcinoma. A proposal for essential site for lymph node biopsy. Cancer 1996;78:803-808

• 16) Williams SD, Stablein DM, Einhorn LH, et al:Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl Med 1987;317:1433-1438

• 17) Dark CG, Bower M, Newlands ES, et al:Surveillance policy for stage I ovarian germ cell tumors. J Clin Oncol 1997;15:620-624

• 18) Kaldor JM, Day NE, Petterson F, et al:Leukemia following chemotherapy for ovarian cancer. N Engl J Med 1990;322:1-6

• 19) Travis LB, Holowaty EJ, Bergfeldt K, et al:Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med 1999;340:351-357

• 20) Young RC, Walton LA, Ellenberg SS, et al:Adjuvant therapy in stage I and stage II epithelial ovarian cancer:Results of two prospective randomized trials. N Engl J Med 1990;322:1021-1027

• 21) Bolis G, Colombo N, Pecorelli S, et al:Adjuvant treatment for early epithelial ovarian cancer:Results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate(32P). Ann Oncol 1995;6(9):887-893
  pubmed

• 22) Young RC, Brady MF, Nieberg RM, et al:Randomized Clinical Trial of Adjuvant Treatment of Women with Early(FIGO-I-IIA High Risk)Ovarian Cancer-GOG #95. Proc Annu Meet Am Soc Clin Oncol 1999;18:abstr 1376

• 23) Gynecologic Oncology Group:Phase III Randomized Study of CBDCA/TAX Administered for 3 vs 6 Courses for Selected Stages IA-C and Stages IIA-C Ovarian Epithelial Cancer(Summary Last Modified 07/98), GOG-157. (インターネットNCI-PDQ)

• 24) Gynecologic Oncology Group:Phase III Randomized Study of Carboplatin and Paclitaxel With or Without Low Dose Paclitaxel in Patients with Early Stage Ovarian Carcinoma(Summary Last Modified 12/98), GOG-175. (インターネットNCI-PDQ)

• 25) Trope C, Kaern J, Vergote I, et al:Randomized trial on adjuvant carboplatin versus no treatment in stage I high risk ovarian cancer by the Nordic Ovarian Cancer Study Group(NOCOVA). Proc Annu Meet Am Soc Clin Oncol 1997;16:abstr 1260

• 26) MRC-ICON:Phase III Randomized Study of Adjuvant Therapy with a Platinum-Containing Regimen(e. g. , CBDCA or CAP:CTX/DOX/CDDP) vs No Adjuvant Therapy in Patients with Fully Resected Early Stage Ovarian Cancer(Summary Last Modified 01/97), MRC-ICON 1, EU-91002. (インターネットNCI-PDQ)

• 27) EORTC:Phase III Randomized Comparison of Adjuvant Platinum-Containing (CDDP or CBDCA with or without Other Agents) vs No Adjuvant Therapy in Patients with Stage I/II Ovarian Epithelial Carcinoma(Summary Last Modified 06/98), EORTC-55904. (インターネットNCI-PDQ)

• 28) Hatae M, Onishi Y, Noda K, et al:Randomized trial on adjuvant iv chemotherapy CDDP+CPA versus po chemotherapy CPA for stage IA ovarian cancer by the Japanese Gynecologic Oncology and Chemotherapy Study Group. Proc Annu Meet. Am Soc Clin Oncol 1997;17:abstr 1260

• 29) DeVita VT:Principles of chemotherapy. Principles and Practice of Oncology (DeVita VT, Hellman S, Rosenberg SA, eds). 2nd ed. 1985;pp257-285, Lippincott. Philadelphia

• 30) van der Burg MEL, van Lent M, Buyse M, et al:The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 1995;332:629-634

• 31) 恒松隆一郎, 笠松達弘:悪性卵巣腫瘍の治療. 産婦人科の実際1973;22134-43

• 32) Piver MS, Baker T:The potential for optimal(≦2cm)cytoreductive surgery in advanced ovarian carcinoma at a tertiary medical center:A prospective study. Gynecol Oncol 1986;24:1-8

• 33) Hoskins WJ, Lawton FG:Primary cytoreductive surgery for advanced-stage disease. Ovarian Cancer Controversies in Management(Gershenson DM, McGuire WP, eds). 1998;pp65-83, Churchill Livingstone, New York

• 34) Cannistra SA:Cancer of the ovary. N Engl J Med 1993;329:1550-1559

• 35) Schwartz PE, Rutherford TJ, Chambers JT, et al:Neoadjuvant chemotherapy for advanced ovarian cancer:Long-term survival, Gynecol Oncol 1999;72:93-99

• 36) Bonnefbi H, A'Hern RP, Fisher C, et al:Natural history of stage IV epithelial ovarian cancer. J Clin Oncol 1999;17:767-775

• 37) Egger M, Davey Smith G:Meta-analysis. BMJ 1997;315:1371-1374, 1533-1537, 1610-1614. 1998;316:61-66, 142-144, 221-225

• 38) Advanced Ovarian Cancer Trialists Group:Chemotherapy in advanced ovarian cancer:An overview of randomised clinical trials. BMJ 1991;303:884-893

• 39) Advanced Ovarian Cancer Trialists Group:Chemotherapy in advanced ovarian cancer:Four systematic meta-analyses of individual patient data from 37 randomized trials. Br J Cancer 1998;78:1479-1487

• 40) Ovarian Cancer Meta-Analyses Project:CP vs CAP chemotherapy of ovarian carcinoma:A meta-analysis. J Clin Oncol 1991;9:1668-1674

• 41) 恒松隆一郎:G-CSF併用 dose-intensive chemotherapy. 産婦人科の世界1996;48:67-73

• 42) McGuire WP, Hoskins WJ, Brady MF, et al:Assessment of dose intensive therapy in suboptimally debulked ovarian cancer:A Gynecologic Oncology Group Study. J Clin Oncol 1995;13:1589-1599

• 43) Kaye SB, Lewis CR, Paul J, et al:Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 1992;340:329-333

• 44) Kaye SB, Paul J, Cassidy J, et al:Mature results of a randomised trial of two doses of cisplatin for the treatment of ovarian cancer. J Clin Oncol 1996;14:329-333

• 45) McGuire WP, Hoskins WJ, Brady MF, et al:Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N Engl J Med 1996;334:1-6

• 46) Stuart G, Bertelsen K, Mangioni C, et al:Updated analysis shows a highly significant overall improved survival for cisplatin-paclitaxel as first line treatment of advanced ovarian cancer:Mature results of the EORTC-GCOG, NOCOVA, NCIC CTG and Scottish Intergroup trial. Proc Annu Meet Am Soc Clin Oncol 1998;17:abstr 1394

• 47) Muggia FM, Brady PS, Brady MF, et al:Phase III of cisplatin or paclitaxel versus the combination in suboptimal stage III and IV epithelial ovarian cancer:Gynecological Oncology Group (GOG) study. Proc Annu Meet Am Soc Clin Oncol 1997;16:abstr 1257

• 48) Harper P, on behalf of the ICON Collaborators:A Randomized Comparison of Paclitaxel and Carboplatin vs Control Arm of Single Agent Carboplatin or CAP(Cyclophosphamide, Doxorubicin and Cisplatin):2075 Patients Randomized into ICON3 Study. Proc Annu Meet Am Soc Clin Oncol 1999;18:abstr 1375

• 49) Sandercock J, Parmar MKB, Torri V:First-line chemotherapy for advanced ovarian cancer:Paclitaxel, cisplatin and the evidence. Br J Cancer 1998;78:1471-1478

• 50) Vermorken JB, Harper PG, Buyse M:The role of anthracyclines in epithelial ovarian cancer. Ann Oncol 1999;10 (suppl 1):S43-S50

• 51) Legros M, Dauplat J, Fleury J, et al:High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer. J Clin Oncol 1997;15:1302-1308

• 52) Arnold K:High-dose chemo and breast cancer:Early results spark debate. J Natl Cancer Inst 1999;91:992-993

• 53) Berek JS, Trope C, Vergote I:Surgery during chemotherapy and relapse of ovarian cancer. Ann Oncol 1999;10 (suppl 1):S3-S7

P.238 掲載の参考文献

• 1) Piver MS, Barbw JJ, Lele SB:Incidence of subclinical metastasis in stage I and II ovarian carcinoma. Obstet Gynecol 1978;52:100-104

• 2) Buchsbaum HJ, Lifshitz S:Staging and surgical evaluation of ovarian cancer. Semin Oncol 1984 11:227-237

• 3) Young RC, Decker DG, Wherton JT, et al:Staging laparotomy in early ovarian cancer. JAMA 1983;250:3072-3076

• 4) 葛谷和夫, 石川尚武, 中西 透, ほか:当院で行っている卵巣癌staging laparotomy-その実際と若干の工夫. 産婦人科手術1997;8:87-96

• 5) Yoshimura S, Scully RE, Bell PA, et al:Correlation of ascitic fluid cytology with histologic findings before and after treatment of ovarian cancer. Am J Obstet Gynecol 1984;148:716-721

• 6) Keettel WC, Pixley EE, Buchsbaum HJ:Experience with peritoneal cytology in the management of gynecologic malignancies. Am J Obstet Gynecol 1974;120:174-182

• 7) Creasman WT, Ruyledge F:The prognostic value of peritoneal cytology ingynecologic malignant disease. Am J Obstet Gynecol 1971;110:773-781

• 8) Jimbo H, Yoshikawa H, Onda T, et al:Prevalence of ovarian endometriosis in epithelial ovarian cancer. Int J Gynaecol Obstet 1997;55:165-166

• 9) Onda T, Yoshikawa H, Yokota H, et al:Assessment of metastases of aortic and pelvic lymph nodes from epithelial ovarian carcinoma:A proposal for essential sites for node biopsy. Cancer 1996;78:803-808

• 10) Onda T, Yoshikawa H, Yasugi T, et al:Patients with ovarian carcinoma upstaged to Stage III after systematic lymphadenectomy have similar survival to Stage I/II patients and superior survival to other Stage III patients. Canccer 1998;83:1550-1560

• 11) Ozols RF:Update of the UCCN ovarian cancer practice guidelines. NCCN proceeding. Oncology 1997;11:95-105

P.248 掲載の参考文献

• 1) Munnell EW:The changing prognosis and treatment in cancer of the ovary. A report of 235 patients with primary ovarian carcinoma 1952-1961. Am J Obstet Gynecol 1968;100:790-805

• 2) 日本産科婦人科学会, 編:卵巣腫瘍取扱い規約-第2部. 1992;p18, 金原出版, 東京

• 3) Griffiths CT:Surgery at the time of diagnosis in ovarian cancer. Management of Ovarian Cancer (Blackledge G, Chan KK, eds). 1986;pp60-72, Butterworth. London

• 4) Griffiths CT:Surgical resection of tumor bulk in the primary treatment of ovarian cancer. Nat Cancer Inst Monogr 1975;42:101
  pubmed

• 5) Pohl R, Dallenback-Hellweg G, Plugge T, et al:Prognostic parameters in patients with advanced ovarian malignant tumors. Eur J Gynaec Oncol 1984;3:160

• 6) Delgado G, Oram DH, Petrilli ES:Stage III epithelial ovarian cancer:The role of maximal surgical reduction. Gynecol Oncol 1984;18:293-298

• 7) Allen DG, Heintz APM, Touw FWMM:A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary. Eur J Gynaec Oncol 1995;16:349-356

• 8) Gall S, Bundy B, Beecham J, et al:Therapy of stage III (optimal)epithelial carcinoma of the ovary with melphalan plus Corynebacterium parvum(a Gynecologic Oncology Group study). Gynecol Oncol 1986;25:26-36

• 9) Hoskins W, Bundy B, Thigpen T, et al:The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer:A Gynecologic Oncology Group study. Gynecol Oncol 1992;47:159-166

• 10) Redman JR, Petroni GR, Saigo PE, et al:Prognostic factors in advanced ovarian cancer. J Clin Oncol 1986;4:515-523

• 11) Potter ME, Partridge EE, Hatch KD, ct al:Primary surgical therapy of ovarian cancer:How much and when. Gynecol Oncol 1991;40:195-200

• 12) 寺島芳輝, 佐々木寛, 横山志郎, ほか:21施設による進行卵巣癌の治療成績-とくに治療法の相違による生存率の差異を中心に. 日本産科婦人科学会雑誌1993;45:363-370

• 13) Van der Burg MEL van Lent M, Kobierska A, et al:Intervension debulking surgery dose improve survival in advanced epithelial ovarian cancer:an EORTC Gynecological Cancer Cooperative Group study. Proc ASCO 1993;12:258

• 14) 清水敬生, 荷見勝彦:FIGO III・IV期悪性卵巣腫瘍に対する治療成績-Neoadjuvant化学療法は有用か? 日本産科婦人科学会雑誌1993;45:1007-1014

• 15) Burke TW, Morris M:Secondary cytoreductive operation. Ovarian Cancer(Rubin ST, Sutton GP, eds). 1993;pp301-312. McGraw-Hill, New York

• 16) 葛谷和夫, 石川尚武, 中西 透:当院で行っている卵巣癌staging laparotomy-その実際と若干の工夫. 産婦人科手術1997;8:87-96

• 17) Onda T, Yoshikawa H, Yokota H, et al:Assessment of metastases to aortic and pelvic lymph nodes in epithelial ovarian carcinoma, a proposal for essential sites for lymph node biopsy. Cancer 1996;78:803-808

• 18) Burghardt E, Pickel H, Lahousen M, et al:Pelvic lymphadenectomy in operative treatment of ovarian cancer. Am J Obstet Gynecol 1986;155:315-319

• 19) Wu PC, Qu JY, Lang JH, et al:Lymph node metastasis of ovarian cancer:A preliminary survey of 74 cases of lymphadenectomy. Am J Obstet Gynecol 1986;155:1103-1108

• 20) 佐々木寛, 落合和徳, 寺島芳輝, ほか:試験開腹か根治手術かの判断基準. 日本産婦人科手術研究会誌1990;1:17-26

• 21) 河島秀昭, 平尾雅紀, 樫山基矢, ほか:骨盤内臓全摘術8例の検討. 北海道外科雑誌1988;34:107-111

• 22) 葛谷和夫:子宮頸癌の手術療法, 第47回日本産科婦人科学会視聴覚セッション. 1995

• 23) 吉川裕之, 武谷雄二:傍大動脈リンパ節郭清術. 婦人科がん治療学(野田起一郎, 編). 1997;pp327-331, 金原出版, 東京

• 24) 田村 学:Pelvic exenteration. 婦人科がん治療学(野田起一郎, 編). 1997;pp303-326, 金原出版, 東京

P.256 掲載の参考文献

• 1) Wangensteen O:Cancer of the colon and rectum with special reference to(1)earlier recognition of a limentary tract malignancy;(2)secondary delayed re-entry of the abdomen in patients exhibiting lymph node involvement:(3)subtotal excision of the colon:(4)operation in obstruction, Wis Med. J 1949;48:591-597

• 2) Wangensteen O, Lewis F, Tongen L:The "second-look" in cancer surgery. J Lancet 1951;71:303-307

• 3) Parks T:Carcinoma of the ovary treated preoperatively with deep X-ray. Am J Obstet Gynecol 1945;49:676-685

• 4) Koumeier H:Radiotherapy in the treatment of ovarian carcinoma. Clin Obstet Gynecol 1961;4:865-874

• 5) Wallach R, Blinick G:The second-look operation for carcinoma of the ovary. Surg Gynecol Obstet 1970;131:1085-1089

• 6) Tepper E, Sanfilippo LJ, Gray J, et al:Second look surgery after radiation therapy for advanced slages ofcancer of the ovary. Am J Roentgenol 1971;112:755-759

• 7) Wallach RC, Kabakow B, Jerez E, et al:The importance of second-look surgical procedures in the staging and treatment of ovarian carcinoma. Semin Oncol 1975;2:243-246

• 8) Stuart GC, Jaffries M, Stuart JL, et al:The changing role of "second look" laparotomy in the management of epithelial carcinoma of the ovary. Am J Obstet Gynecol 1982;142:612-616

• 9) Raju KS, McKinna JA, Barker GH, et al:Second-look operations in the planned management of advanced ovarian carcinoma. Am J Obstet Gynecol 1982;144:650-654

• 10) Luesley DM, Chan KK, Fielding JW, et al:Second look laparotomy in the management of epithelial ovarian carcinoma:An evaluation of fifty cases. Obstet Gynecol 1984;64:421-426

• 11) Smith JP, Delgado G, Rutledge F:Second-look operation in ovarian carcinoma:Postchemotherapy, Cancer 1976;38:1438-1442

• 12) Dauplat J, Ferriere JP, Gorbinet M, et al:Second-look laparotomy in managing epithelial ovarian carcinoma. Cancer 1986;57:1627-1631

• 13) Arhelger S, Jenson C, Wangensteen O:Experiences with the "second look" procedure in the management of cancer of the colon and rectum. Lancet 1957;ii:412-417

• 14) Kaslow R, Wisch N, Glass J:Acute leukemia following cytotoxic chemotherapy. JAMA 1972;219:75-76

• 15) Reimer R, Hoover R, Fraumeni JJ, et al:Acute leukemia after alkylating-agent therapy of ovarian cancer. N Engl J Med 1977;297:177-181

• 16) Wihshaw E, Kroner T:Phase II study of cis-dichlorodiamineplatinum in advanced adenocarcinoma of the ovary. Cancer Treat Rep 1976;60:55-60

• 17) Bruckner H, Cohell C, Gusberg S, et al:Chemotherapy of ovarian cancer with adriamycin and cis platinum. Proc Am Soc Clin Oncol 1976;17:287

• 18) Pettersson F:Annual report on the results of treatment in gynecological cancer. Stockholm:International Federation of Gynecology and Obstetrics, 1988

• 19) Bergman F:Carcinoma of the ovary. A clinicopathological study of 86 autopsied cases with special reference to mode of spread. Acta Obstet Gynecol Scand 1966;45:211-231

• 20) 日本産科婦人科学会, 編:卵巣腫瘍取扱い規約-第2部, 改訂第2版. 1997;p22, 金原出版, 東京

• 21) 落合和徳, 高倉 聡, 篠崎英雄, ほか:卵巣癌staging laparotomyの手技. 産婦人科手術1997;8:71-78

• 22) ACOG Committee opinion:Second-look laparotomy for epithelial ovarian cancer. Number 165, December 1955. Committee on Gynecologic Practice. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 1996;53(1):81-83

• 23) Schwartz PE, Smith JP:Second-look operations in ovarian cancer. Am J Obstet Gynecol 1980;138:1124-1130

• 24) Curry S, Zembo M, Nahhas W, et al:Second-look laparotomy for ovarian cancer. Gynecol Oncol 1981;11:114-118

• 25) Roberts WS, Hodel K, Rich WM, et al:Second-look laparotomy in the management of gynecologic malignancy. Gynecol Oncol 1982;13:345-355

• 26) Webb MJ, Snyder JJ, Williams TJ, et al:Second-look laparotomy in ovarian cancer. Gynecol Oncol 1982;14:285-293

• 27) Phibbs GD, Smith JP, Stanhope CR:Analysis of sites of persistent cancer at "second-look" laparotomy in patients with ovarian cancer. Am J Obstet Gynecol 1983;147:611-617

• 28) Ballon SC, Portnuff JC, Sikic BI, et al:Second-look laparotomy in epithelial ovarian carcinoma:Precise definition, sensitivity, and specificity of the operative procedure. Gynecol Oncol 1984;17:154-160

• 29) Barnhill DR, Hoskins WJ, Heller PB, et al:The second-look surgical reassessment for epithelial carcinoma. Gynecol Oncol 1984;19:148-154

• 30) Rocereto TF, Mangan CE, Giuntoli RL, et al:The second-look celiotomy in ovarian cancer. Gynecol Oncol 1984;19:34-45

• 31) Podratz KC, Malksian G Jr, Hilton JF, et al:Second-look laparotomy in ovarian cancer:Evaluation of pathologic variables. Am J Obstet Gynecol 1985;152:230-238

• 32) Smirz LR, Stehman FB, Ulbright TM, et al:Second-look laparotomy after chemotherapy in the management of ovarian malignancy. Am J Obstet Gynecol 1985;152:661-668

• 33) Gershenson DM, Copeland LJ, Wharton JT, et al:Prognosis of surgically determined complete responders in advanced ovarian cancer. Cancer 1985;55:1129-1135

• 34) Cain J, Saigo P, Peierce V, et al:A review ofsecond-look laparotomy for ovarian cancer. Gynecol Oncol 1986;23:14-25

• 35) Gall S, Bundy B, Beecham J, et al:Therapy of stage III (optimal)epithelial carcinoma of the ovary with melphalan or melphalan plus Corynebacterium parvum. Gynecol Oncol 1986;25:26-36
  pubmed

• 36) Carmichael JA, Shelley WE, Brown LB, et al:A predictive index of cure versus no cure in advanced ovarian carcinoma patients-Replacement of second-look laparotomy as a diagnostic test, Gynecol Oncol 1987;27:269-281

• 37) Gallup DG, Talledo OE, Dudzinski MR, et al:Another look at the second-look at the second-assessment procedure for ovarian epithelial carcinoma. Am J Obstet Gynecol 1987;157:590-596

• 38) Podczaski ES, Steves CJ, Manetta A, et al:Use of second-look laparotomy in the management of patients with ovarian epithelial malignancies. Gynecol Oncol 1987;28:205-214

• 39) McCusker MC, Hofrman JS, Curry SL, et al:The role of second-look laparotomy in treatment of epithelial ovarian cancer. Gynecol Oncol 1987;28:83-88

• 40) Walton L, Ellenberg SS, Major F Jr, et al:Results of second-look laparotomy in patients with early stage ovarian carcinoma. Obstet Gynecol 1987;70:770-773

• 41) Free KE, Webb MJ:Second-look laparotomy:Clinical correlations. Gynecol Oncol 1987;26:290-297

• 42) Chambers SK, Chambers JT, Kohorn EI, et al:Evaluation of the role of second-look surgery in ovarian cancer. Obstet Gynecol 1988;72:404-408

• 43) Sonnendecker EW:Is routine second-look laparotomy for ovarian cancer justified? Gynecol Oncol 1988;31:249-255

• 44) Lippman SM, Alnerts DS, Slymen DJ, et al:Second-look laparotomy in epithelial ovarian carcinoma:Prognostic factors associated with survival duration. Cancer 1988;61:2571-2577

• 45) Podratz KC, Schray MF, Wieand HS, et al:Evaluation of treatment survival after positive second-look laparotomy. Gynecol Oncol 1988;31:9-24

• 46) Krag KJ, Canellos GP, Grifhths CT, et al:Predictive factors for long-term survival in patients with advanced ovarian cancer. Gynecol Oncol 1989;34:88-93

• 47) Kamura T, Tsukamoto N, Saito T, et al:Efficacy of second-look laparotomy for patients with epithelial ovarian carcinoma. Int J Gynaecol Obstet 1990;33:141-147

• 48) Lund B, Williamson P:Prognostic factors for outcome of and survival after second-look laparotomy in patients with advanced ovarian carcinoma. Obstet Gynecol 1990;76:617-622

• 49) Podczaski E, Manetta A, Kaminski P, et al:Survival of patients with ovarian epithelial carcinoma after second-look laparotomy. Gynecol Oncol 1990;36:43-47

• 50) Ayhan A, Yarali H, Develioglu O, et al:Prognosticators of second-look laparotomy findings in patients with epithelial ovarian cancer. J Surg Oncol 1991;46:222-225

• 51) Potter ME, Hatch KD, Soong S-J, et al:Second-look laparotomy and salvage therapy:A research modality only? Gynecol Oncol 1992;44:3-9

• 52) Gallion HH, Hunter JE, van Nagell JR, et al:The prognostic implications of low serum CA125 levels prior to the second-look operation for stage III and IV epithelial ovarian cancer. Gynecol Oncol 1992;46:29-32

• 53) Rubin SC, Jones WB, Curtin JP, et al:Second-look laparotomy in stage I ovarian cancer following comprehensive surgical staging. Obstet Gynecol 1993;82(1):139-142

• 54) 西村治夫, 大蔵尚文, 薬師寺道明, ほか:卵巣癌に対するSecond-look operation(SLO)の評価-287例を対象として. 日本癌治療学会誌, 1995;30:1721-1728

• 55) Tuxen MK, Strauss G, Lund B, et al:The role of second-look laparotomy in the long-term survival in ovarian cancer. Ann Oncol 1997;8(7):643-648

• 56) Hempling RE, Wesolowski JA, Piver MS:Second-look laparotomy in advanced ovarian cancer:A critical assessment of morbidity and impact on survival. Ann Surg Oncol 1997;4(4):349-354

• 57) Friedman RL, Eisenkop SM, Wang HJ:Second-look laparotomy for ovarian cancer provides reliable prognostic information and improves survival. Gynecol Oncol 1997;67(1):88-94

• 58) 高倉 聡, 落合和徳, 塩塚重正, ほか:卵巣癌根治術後のセカンドルック手術の意義. 日本産科婦人科学会雑誌1998;50:111-118

• 59) 牛嶋公生, 杉山 徹, 西田 敬, ほか:上皮性卵巣癌に対するsecond-look operation(SLO)の意義と問題点. 日本産科婦人科学会雑誌1999;51:119-126

• 60) Rubin SC:Second-look laparotomy in ovarian cancer. Caricer of Ovary(Markman M, Hoskins WL, eds). 1993, Raven Press, New York

• 61) Berek JS, Hacker NF, Lagasse LD, et al:Second-look laparotomy in stage III epithelial ovarian cancer:Clinical variable associated with disease status. Obstet Gynecol 1984;64:207-212

• 62) Copeland LJ, Gershenson DM:Ovarian cancer recurrences in patients with no macroscopic tumor at second-look laparotomy. Obstet Gynecol 1986;68:873-874

• 63) Miller DS, Ballon SC, Teng NN, et al:A critical reassessment of second-look laparotomy in epithelial ovarian carcinoma. Cancer 1986;57:530-535

• 64) Potkul PK, Delgado G, Petrilli ES, et al:Ovarian carcinoma. The significance of restaging laparotomies with negative outcomes. Arch Surg 1986;121:1262-1264

• 65) Omura G, Blessing JA, Ehrlich CE, et al:A randomized trial of cyclophosphamid and doxorubicin with or without cisplatin in advanced ovarian carcinoma. Cancer 1986;57:1725-1730
  pubmed

• 66) Podratz KC, Malkasian GJ, Wieand HS, et al:Recurrent disease after negative second-look laparotomy in stages III and IV ovarian carcinoma. Gynecol Oncol 1988;29:271-282

• 67) Rubin SC, Hoskins WJ, Hakes TB, et al:Recurrence after negative second-look laparotomy for ovarian cancer:Analysis of risk factors. Am J Obstet Gynecol 1988;159:1094-1098

• 68) Luesley DM, Chan KK, Kawton FG, et al:Survival after negative second-look laparotomy. Eur J Surg Oncol 1989;15:205-210

• 69) Ayhan A, Urman B, Yarali H, et al:Predictors of recurrent disease after negative second-look laparotomy for epithelial ovarian cancer. J Surg Oncol 1990;44:119-121

• 70) Ghatage P, Krepart GV, Lotocki R:Factoranalysis of false-negative second-look laparotomy. Gynecol Oncol 1990;36:172-175

• 71) Rubin SC, Hoskins WJ, Saigo PE, et al:Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients treated with platinum-based chemotherapy. Gynecol Oncol 1991;42:137-141

• 72) Maggino T, Gadducci A, Romagnolo C, et al:Times and sites of relapses after negative second look in advanced epithelial ovarian cancer. Eur J Surg Oncol 1994;20:146-150

• 73) Rubin SC, Randall TC, Armstrong KA, et al:Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. Obstet Gynecol 1999;93(1):21-24

• 74) Rubin SC, Lewis JJ:Second-look surgery in ovarian cancer. Crit Rev Oncol Hemiatol 1988;8:75-91

• 75) Katsoulis M, Vorgias G, Panagiotides J, et al:The prognostic significance of second-look laparotomy in advanced ovarian cancer. Eur J Gynaecol Oncol 1997;18(3):200-202

• 76) Hoskins WJ, Rubin SC, Dulaney E, et al:In Huence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma. Gynecol Oncol 1989;34:365-371

• 77) Williams L, Brunetto VL, Yordan E et al:Secondary cytoreductive surgery at second-look laparotomy in advanced ovarian cancer:A Gynecologic Oncology Group Study. Gynecol Oncol 1997;66(2):171-178

• 78) Bristow RE, Lagasse LD, Karlan BY:Secondary surgical cytoreduction for advanced epithelial ovarian cancer. Patient selection and review of the literature. Cancer 1996;78(10):2049-2062

• 79) Kuhn W, Schmalfeldt B, Pache L, et al:Disease-adapted relapse therapy for ovarian cancer:Results of a prospective study. Int J Oncol 1998;13(1):57-63

• 80) McGowan L, Bunnag B:The evaluation of therapy for ovarian cancer. Gynecol Oncol 1976;4:375
  pubmed

• 81) Goldberg G, Learmonth G, Bloch B, et al:Role of cul-de-sac aspiration cytology in the management and follow-up of patients with ovarian carcinoma. A preliminary report. J Reprod Med 1985;30:867-870

• 82) Rubin SC, Dulaney ED, Markman M, et al:Peritoneal cytology as an indicator of disease in patients with residual ovarian carcinoma. Obstet Gynecol 1988;71:851-853

• 83) Fujiwara K, Yamauchi H, Yoshida T, et al:Relationship between peritoneal washing cytology through implantable port system(IPS-cytology)and second-look laparotomy in ovarian cancer patients with unmeasurable residual diseases. Gynecol Oncol 1988;70:231-235

• 84) Brenner DE, Shaff MI, Jones HW, et al:Subdominopelvic computed tomography:Evaluation in patients undergoing second-look laparotomy for ovarian carcinoma. Obstet Gynecol 1985;65:715-719

• 85) Murolo C, Constantini S, Foglia G, et al:Ultrasound examination in ovarian cancer patients. A comparison with second look laparotomy. J Ultrasound Med 1989;8:441-443

• 86) Bast RC Jr, Klug TL, St John E, et al:A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309:883-887

• 87) Meier W, Stieber P, Eiermann W, et al:Serum levels of CA125 and histological findings at second-look laparotomy in ovarian carcinoma. Gynecol Oncol 1989;35:44-46

• 88) Childers JM, Lang J, Surwit EA, et al:Laparoscopic surgical staging of ovarian cancer. Gynecol Oncol 1995;59(1):25-33

• 89) Abu-Rustum NR, Barakat RR, Siegel PL, et al:Second-look operation for epithelial ovarian cancer. Laparoscopy or laparotomy? Obstet Gynecol 1996;88:549-553
  pubmed

P.271 掲載の参考文献

• 1) Cline MJ, Haskell CM:Cancer Chemotherapy. 1980. WB Saunders, Philadelphia, London, Toronto

• 2) Rosenberg B, Van Camp L, Krigas T:Inhibition of cell division in Escherichiacoli by electrolysis products by platinum electrode. Nature 1965;205:698

• 3) Muggia FM:Cisplatin update. Semin Oncol 1991;18:1-4

• 4) Calvert AH, Newell DR, Gumbrell LA, et al:Carboplatin dosage:Prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-1756

• 5) Priestman TJ:Cancer Chemotherapy:An introduction, 3rd ed. 1988, Springer-Verlag, London, New York, Tokyo

• 6) Parness J, Horwitz SB:Taxol binds to polymerized microtubules in vitro. J Cell Biol 1981;97:479-484

• 7) Roberts JR, Allison DC, Donehower RC, et al:Development of polyploidization in taxolresistant human leukemia cells in vitro. Cancer, Res 1990;50:710-716

• 8) Tsuruo T, Matsuzaki T, Matsushita M, et al:Antitumor effect of CPT-II, a new derivative of camptothecin, against pleiotropic drug-resistant tumor in vitro and in vivo. Cancer Chemother Pharmacol 1988;21:71-74

• 9) Omura G, Blessing J, Ehrlich CE, et al:A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study. Cancer 1986;57:1725-1730
  pubmed

• 10) Hakes TB, Chalas E, Hoskins WJ, et al:Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecol Oncol 1992;45:284-289

• 11) Bertelsen K, Jakobsen A, Stroyer J, et al:A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer:A Danjsh Ovarian Study Group trial(DACOVA). Gynecol Oncol 1993;49:30-36

• 12) Thigpen JT:Ovarian cancer and fallopian tubes. Clinical Oncology(Abelofr M, Armitage JO, Lichter AS, et al, eds). 1995;pp1595-1615, Churchill Livingstone, New York, Edinburgh, London

• 13) Hunter RW, Alexander ND, Soutter WP:Meta-analysis of surgery in advanced ovarian carcinoma:Is maximum cytoreductive surgery an independent determinant of prognosis? Am J Obstet Gynecol 1992;166:504-511

• 14) Partridge EE, Phillips JL Menck HR:The National Cancer Data Base report on ovarian cancer treatment in United States hospitals. Cancer 1996;78:2236-2246

• 15) Young RC, Walton LA, Ellenberg SS, et al:Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 1990;322:1021-1027

• 16) NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. JAMA 1995;273:491-497

• 17) Jacob JH, Gershenson DM, Morris M, et al:Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. Gynecol Oncol 1991;42:146-150

• 18) Van der Burg MEL, Van Lent M, Buyse MBA, et al:The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 1995;332:629-634

• 19) Omura G, Bundy B, Wilbanks G, et al:A randomized trial of cyclophosphamide plus cisplatin with or without adriamycin in ovarian carcinoma. Proc ASCO 1987;6:112

• 20) Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma:Ameta-analysis. The Ovarian Cancer Meta-Analysis Project J Clin Oncol 1991;9:1668-1674

• 21) A'Hern RP, Gore ME:Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol 1995;13:726-732

• 22) McGuire WP, Hoskins WJ, Brady MF, et al:Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage IV and stage IV ovarian cancer. N Engl J Med 1996;334:1-6

• 23) Neijt JP, Engelholm SA, Witteveen PO, et al:Paclitaxel(175 mg/m2 over 3 hours)with cisplatin or carboplatin in previously untreated ovarian cancer:An interim analysis. Semin Oncol 1997;24:36-39
  pubmed

• 24) Bois A, Luck HJ, Meier W, et al:Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer. Semin Oncol 1997;24:44-52

• 25) Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al:European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer:high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994;12:2654-2666

• 26) Siddiqui N, Boddy AV, Thomas HD, et al:A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer. Br J Cancer 1997;75:287-294

• 27) Warmerdam LJC, Huizing MT, Giaccone G, et al:Clinical pharmacology of carboplatin administrated in combination with paclitaxel. Semin Oncol 1997;24:97-104

• 28) Calvert AH:A review of the pharmacokjnetic and pharmacodynamics of combination carbonplatin/paclitaxel. Semin Oncol 1997;24:85-90

• 29) Ozols RT:Update of the NCCN ovarian cancer practice guidelines. Oncology 1997;11:95-100

• 30) Kigawa J, Minagawa Y, Ishihara H, et al:Tumor DNA ploidy and prognosis of patients with serous cystadenocarcinoma of the ovary. Cancer 1993;72:804-808

• 31) Muggia FM:Cisplatin update. Semin Oncol 1991;18:1-4

• 32) Bokkel H, Gore M, Carmicheal J, et al:Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997;15:2183-2193

• 33) Rose PG, Blessing J, Mayer AR, et al:Prolonged oral etoposide as second line chemotherapy for platinum resistant and platinum sensitive ovarian carcinoma:A gynecologic group study. J Clin Oncol 1998;16:405-410

• 34) Creemers GJ, Bolis G, Scarfone G, et al:Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer:Results of a large European phase II study. J Clin Oncol 1996;14:1552-1557

• 35) Minagawa Y, Kigawa J, Ishihara H, et al:Synergistic enhancement of cisplatin cytotoxicity by SN-38, an active metabolite of CPT-11, for cisplatin-resistant Hela cells. Jpn J Cancer Res 1994;85:966-971

• 36) Sugiyama T, Yakushiji M, Kigawa J, et al:Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer. Cancer Lett 1998;128:211-218
  pubmed

• 37) Kigawa J, Minagawa Y, Kanamori Y, et al:Glutathione concentration may be a useful predictor of second-line chemotherapy in patients with ovarian cancer. Cancer 1998;82:697-702

• 38) Levin L, Simon R, Hryniuk W:Importance of multiagent chemotherapy regimens in ovarian carcinoma. J Natl Cancer Inst 1993;85:1732-1742

• 39) McGuire WP, Hoskins W, Brady M, et al:Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer:A gynecologic oncology study. J Clin Oncol 1995;13:1589-1599

• 40) Conte P, Bruzzone M, Carnino F, et al:High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer. J Clin Oncol 1996;14:351-356

• 41) Jakobsen A, Bertelsen K, Andersen JE, et al:Dose-effect study of carboplatin in ovarian cancer:A Danish ovarian cancer group study. J Clin Oncol 1997;15:193-198

• 42) Stiff PJ, Bayer R, Kerger C, et al:High-dose chemotherapy with autologous transplantation for persistent-relapsed ovarian cancer:A multivariate analysis of survival for 100 consecutively treated patients. J Clin Oncol 1997;15:1309-1317

• 43) Thigpen JT:Dose-intensity in ovarian cancer:Hold, enough? J Clin Oncol 1997;1511291-1293

• 44) Dedrick RL, Flessner MF:Pharmacokinetic problems in peritoneal drug administration:Tissue penetration and surface exposure. J Natl Cancer Inst 1997;89:480-487

• 45) Albert DS, Liu PY, O'Toole R, et al:Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335:1950-1955

• 46) Markman M:Intraperitoneal chemotherapy in the treatment of ovarian cancer. Ann Med 1996;28:293-296

• 47) Markman M, Bundy B, Benda J, et al:Randomized phase III trial study of intravenous cisplatin/paclitaxel versus moderately high dose IV carboplatin followed by IV paclitaxel and intraperitoneal cisplatin in optimal residual ovarian cancer. An intergroup trial(COG, SWOG, ECOG). Proc Am Soc Clin Oncol 1998;17:361

• 48) Kigawa J, Minagawa Y, Itamochi H, et al:Combination effect of granisetron and methylpred nisolone for preventing emesis induced by cytotoxic agents. Gynecol Obstet Invest 1996;43:195-199

• 49) Andrews PA, Velury S, Mann SC, et al:Cis-diamminedichloroplatinum (II) accumulation in sensitive and resistant human ovarian carcinoma cell. Cancer Res 1988;48:68-73

• 50) Andrews PA, Howell SB:Cellular pharmacology of cisplatin:Perspectives on mechanisms of acquired resistance. Cancer Cells 1990;2:35-43

• 51) Ishikawa T, Boo JJ, Yamane Y, et al:Coordinated induction of MRP/GS-X pump and y-glutamylcysteine synthetase by heavy metals in human leukemia cells. J Biol Chem 1996;271:14981-14988

• 52) Masuda H, Ozols RF, Lai GM, et al:Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. Cancer, Res 1988;48:5713-5716

• 53) Herod O, Eliopoulos AG, Warwick J, et al:The prognostic significance of Bcl-2 and p53 expression in ovarian cancer. Cancer Res 1996;56:2178-2184

• 54) Andrews PA, Mann SC, Huynh HH, et al:Role of the Na, K adenosine triphosphatase in the accumulation of cis-diamminedichloroplatinum (II) in human ovarian carcinoma cells. Cancer Res 1991;51:3677-3681

• 55) Hamada S, Kamada M, Furumoto H, et al:Expression of glutathione S-transferase-π in human ovarian cancer as an indicator of resistance to chemotherapy. Gynecol Oncol 1994;52:313-319

• 56) Cheng X, Kigawa J, Minagawa Y, et al:Glutathione S-transferase-π expression and glutathione concentration in ovarian carcinoma before and after chemotherapy. Cancer 1997;79:521-527

• 57) Kigawa J, Minagawa Y, Cheng X, et al:Gamma-glutamyl cysteine synthetase up-regulates glutathione and multidrug resistance-associated protein in patients with chemoresistant epithelial ovarian cancer. Clin Cancer Res 1998;4:1737-1741

• 58) Eastman A, Schulte N:Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum (II). Biochemistry 1988;27:4730-4734

• 59) Kastan MB, Canman CE, Leonard CJ:p53 cell cycle control and apoptosis:Implications for cancer. Cancer Metastasis Rev 1995;14:3-15

• 60) Man S, Bani MR, Adachi D, et al:Retroviral insertional mutagenesis as a strategy for the identification of genes associated with cis-diamminedichloroplatinum (II) resistance. Cancer Res 1995;55:1139-1145

• 61) Perego P, Giarola M, Righetti SC, et al:Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 1996;56:556-562

• 62) Kanamori Y, Kigawa J, Minagawa Y, et al:A newly developed adenovirus-mediated transfer of a wild-type p53 gene increases sensitivity to cis-diamminedichloroplatinum (II) in p53-deleted ovarian cancer cells. Eur J Cancer 1998;34:1802-1806

P.281 掲載の参考文献

• 1) Stadel BV:The etiology and prevention of ovarian cancer. Am J Obstet Gynecol 1975;123:772-774

• 2) Cramer DW, Welch WR:Determinants of ovarian cancer risk. II. Inferences regarding path-ogenesis. J Natl Cancer Inst 1983;71:717-721

• 3) MacDonald PC, Grodin JM, Edman CD, et al:Origin of estrogen in a postmenopausal woman with a nonendocrine tumor of the ovary and endometrial hyperplasia. Obstet Gynecol 1976;47:644-650

• 4) Gondos B:Surface epithelium of the developing ovary. Am J Pathol 1975;81:303-320

• 5) Wynder EL, Dodo H, Barber HR:Epidemiology of cancer of the ovary. Cancer 1969;23:352-370

• 6) Annergers JF, O'Fallon W, Kurland LT:Exogenous oestrogens and ovarian cancer. Lancet 1977;ii:869-870

• 7) Adami HO, Persson I, Hoover R, et al:Risk of cancer in women receiving hormone replacement therapy. Int J Cancer 1989;44:833-839

• 8) Hartge P, Hoover R, McGowan L, et al:Menopause and ovarian cancer. Am J Epidemiol 1988;127:990-998

• 9) Weiss NS, Lyon JL, Krishnamurthy S, et al:Non-contraceptive estrogen use and the occurrence of ovarian cancer. J Natl Cancer 1982;68:95-98

• 10) Hoover R, Gray LA, Fraumeni JF Jr, et al:Stilboestrol (diethylstilbestrol) and the risk of ovarian cancer. Lancet 1977;ii:533-534

• 11) Rao BR, Slotman BJ:Endocrine factors in common epithelial ovarian cancer. Endocr Rev 1991;12:14-26

• 12) Greenblatt RB, Colle ML, Mahesh VB:Ovarian and adrenal steroid production in the post-menopausal woman. Obstet Gynecol 1976;47:383-387

• 13) Kuhnel R, Delemarre JF, Rao BR, et al:Correlation of aromatase activity and steroid receptors in human ovarian carcinoma. Anticancer Res 1983;6:889-892

• 14) Teufel G:Oestrogen und progesteron rezeptoren in malignen ovarialtumoren. Geburtshilfe Frauenkrankhieten 1983;43:732-740

• 15) Iversen OE, Skaarland E, Utaaker E:Steroid receptor content in human ovarian tumors:Survival of patients with ovarian carcinoma related to steroid receptor content. Gynecol Oncol 1986;23:65-76

• 16) Slotman BJ, Baak JP, Rao BR:Correlation between nuclear DNA content and steroid receptor status in ovarian cancer. Eur J Obstet Gynecol, Reprod Biol 1991;38:221-227

• 17) Iversen OE:Prognostic value of the flow cytometric DNA index in human ovarian carcinoma. Cancer 1988;61:971-975

• 18) Slotman BJ, Kuhnel R, Rao BR, et al:Importance of steroid receptors and aromatase activity in the prognosis of ovarian cancer:High tumor progesterone receptor levels correlate with longer survival. Gynecol Oncol 1989;33:76-81

• 19) Pujol P, Rey JM, Nirde P, et al:Differential expression of estrogen receptor-alpha and-beta messenger RNAs as a potential marker of ovarian carcinogenesis. Cancer Res 1998;58:5367-5373

• 20) Lau KM, Mok SC, Ho SM:Expression of human estrogen receptor-alpha and-beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc Natl Acad Sci USA 1999;96:5722-5727

• 21) Kinoshita K, Sakamoto H, Satoh K:Steroid hormone receptors and multi-drug resistant genes expression in gynecologic cancers. The Nihon University Journal of Medicine 1999;41:1-14

• 22) Fan S, Wang J, Yuan R, et al:BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 1999;248:1354-1356

• 23) Mangioni C, Franceschi S, La Vecchia C, et al:High-dose medroxyprogesterone acetate(MPA) in advanced epithelial ovarian cancer resistant to first-or second-line chemotherapy. Gynecol Oncol 1981;12:314-318
  pubmed

• 24) Rendina GM, Donadio C, Giovannini M:Steroid receptors and progestinic therapy in ovarian endometrioid carcinoma. Eur J Gynaecol Oncol 1982;3:241-246

• 25) Freedman RS, Saul PB, Edwards CL, et al:Ethinyl-estradiol and medroxyprogesterone acetate in patients with epithelial ovarian carcinoma:A phase II study. Cancer Treat Rep 1986;70:369-373

• 26) Fromm GL, Freedman RS, Fritsche HA, et al:Sequentially administrated ethinyl estradiol and medroxyprogesterone acetate in the treatment of refractory epithelial ovarian carcinoma in patients with positive estrogen receptors. Cancer 1991;68:1885-1889

• 27) Jakobsen A, Bertelsen K, Sell A:Cyclic hormonal treatment in ovarian cancer. A phase-II trial. Eur J Cancer Clin Oncol 1987;23:915-916

• 28) Belinson JL, McClure M, Badger G:Randomized trial of megestrol acetate vs megestrol acetate/tamoxifen for the management of progressive or recurrent epithelial ovarian carcinoma. Gynecol Oncol 1987;28:151-155
  pubmed

• 29) Myers AM, Moore GE, Major FJ:Advanced ovarian carcinoma:Response to antiestrogen therapy. Cancer 1981;48:2368-2370

• 30) Schwartz PE, Keating G, MacLusky N, et al:Tamoxifen therapy for advanced ovarian cancer. Obstst Gynecol 1982;59:583-588

• 31) Weiner SA, Alberts DS, Surwit EA, et al:Tamoxifen therapy in recurrent epithelial ovarian carcinoma. Gynecol Oncol 1987;27:208-213

• 32) Landoni F, Lacobelli S, Scambia G, et al:Hormonal treatment in advanced ovarian cancer. Anti-oestrogens in Oncology. Past, Present and Prospectives (Panutti F, ed). 1985;pp262-267, Excerpta Medica, Amsterdam

• 33) Shirey DR, Kavanagh JJ Jr, Gershenson DM, et al:Tamoxifen therapy of epithelial ovarian cancer. Obstet Gynecol 1985;66:575-578

• 34) Schwartz PE, Chambers JT, Kohorn EI, et al:Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer. A prospective randomized trial. Cancer 1989;63:1074-1078

• 35) Kenneth D, et al:Responsiveness of patients with advanced epithelial ovarian cancer to tamoxifen.

• 36) Markman M, Iseminger KA, Hatch KD, et al:Tamoxifen in platinum-refractory ovarian cancer:A Gynecologic Oncology Group Ancillary Report. Gynecol Oncol 1996;62:4-6
  pubmed

• 37) Slotman BJ, et al:Primary human ovarian adenocarcinoma:Response to steroids and antihormone in vitro. Cancer 1989;2:2373-2377

• 38) Rao BR, et al:Hormones in ovarian cancer:Update 1993. Endocr Rev 1993;1:188-189

• 39) Simon WE, Albrecht M, Hansel M, et al:Cell lines derived from human ovarian carcinomas:Growth stimulation by gonadotropic and steroid hormones. J Natl Cancer Inst 1983;70:839-845

• 40) 上原茂樹, ほか:卵巣癌とホルモン. 産科と婦人科1982;49:89-92

• 41) 大谷 香, 坂元秀樹, 佐藤和雄, ほか:卵巣癌細胞に対するfollicular stimulating hormone (FSH)のin vitro, in vivoの増殖促進作用. 日本産科婦人科学会雑誌1992;44:579-584

• 42) 大谷 香:ヒト悪性卵巣腫瘍のhormone感受性に関する研究. 日本産科婦人科学会雑誌1990;42:579-584

• 43) Emons G, Ortmann O, Teichert HM, et al:Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial, Decapeptyl Ovarian Cancer Study Group. Cancer 1996;78:1452-1460

• 44) Eeles R, Tan S, Wiltshaw E, et al:Hormone replacement therapy and survival after surgery for ovarian cancer. BMJ 1991;302:259-262

P.291 掲載の参考文献

• 1) Marchand M, Weynants P, Rankin E, et al:Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 1995;63:883-885

• 2) Rosenberg SA, Yang JC, Schwartzentruber DJ, et al:Immunologic and therapeutic evaluation of asynthetic peptide vaccine for the treatment of patients with metastatic melanoma. Natl Med 1998;4:321-327

• 3) Nestle FO, Alijagic S, Gilliet M, et al:Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Natl Med 1998;4:328-332
  pubmed

• 4) Old LJ:ガン免疫療法の可能性. 別冊日経サイエンス124, ガンはここまで治る. 1998;pp110-118, 日経サイエンス社, 東京

• 5) 菊地浩吉:癌の免疫療法. 医科免疫学. 1995;pp329-332, 南江堂, 東京

• 6) 今井浩三, 日野田裕治, 晴山雅人:免疫学的治療法. 臨床免疫学. 1997;pp242-245, 朝倉書店, 東京

P.302 掲載の参考文献

• 1) Pecorelli S, Odicino F, Maisonneuve P, et al:Annual Report on the Results of Treatment in Gynaecologic Cancer, vol 23. Milan, International Federation of Gynecology and Obstetrics. J Epiderniol Biostat 1998;3;75-102

• 2) Alberts DS, Dahlberg S, Green SJ, et al:Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin-cyclophosphamide versus carboplatin-cyclo-phosphamide in stages III (suboptimal) and IV ovarian cancer. A Southwest Oncology Group study. Cancer 1993;71:618-627

• 3) Yancik R:Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer 1993;71:517-523

• 4) Rodriguez M, Nguyen HN, Averett H, et al:National survey of ovarian cancer XII. Epithehal ovarian malignancies in women less than or equal to 25 years of age. Cancer 1994;73:1245-1250

• 5) Massi D, Susini T, Savino L, et al:Epithelial ovarian tumors in the reproductive age group:Age is not an independent prognostic factor. Cancer 1996;77:1131-1136
  pubmed

• 6) Pettersson F, Kolstad P, Ludwig H, et al:Annual Report on the Results of Treatment in Gynecological Cancer, vol 20. Stockholm, International Federation of Gynecology and Obstetrics, 1988.

• 7) Hogberg T, Carstensen J, Simonsen E:Treatment results and prognostic factors in a population-based study of epithelial ovarian cancer. Gynecol Oncol 1993;48:38-49

• 8) Nguyen HN, Averette HE, Hoskins W, et al:National survey of ovarian carcinoma VL Critical assessment of current International Federation of Gynecology and Obstetrics staging system. Cancer 1993;72:3007-3011

• 9) Ahmed FY, Wiltshow E, H'Hern RP, et al:Natural history of prognosis of untreated stage I epithelial ovarian carcinoma. J Clin Oncol 1996;14:2968-2975

• 10) Sainz de la Cuesta R, Goff BA, Fuller AF, et al:Prognostic importance of intraoperative rupture of malignant ovarian epithelial neoplasms. Obstet Gynecol 1994;84:1-7

• 11) Dembo AJ, Davy M, Stenwig A, et al:Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet Gynecol 1990;75:263-272

• 12) O'Brien MER, Schofield JB, Tan S, et al:Clear cell epithelial ovarian cancer (mesonephroid):Bad prognosis only in early stages. Gynecol Oncol 1993;49:250-254

• 13) Berek JS, Fu YS, Hacker NF:Ovarian Cancer (Berek JS, Adashi EY, Hillard PA, eds). Novak's Gynecology, 12th ed. 1996;pp1155-1230, Williams & Wilkins, Baltimore

• 14) International Federation of Gynecology and Obstetrics:Classification and staging of malignant tumors in the female pelvis. Acta Obstet Gynecol Scand 1971;50:1-7

• 15) Serov SF, Scully RE, Sobin LH(eds):Histological typing of ovarian tumours. International Histological Classification of Tumours, No 9. 1973;pp17-54, World Health Organization, Geneva

• 16) Benda JA, Zaino R:GOG Pathology Manual 1994, Gynecologic Oncology Group, Bufralo, New York

• 17) Shimizu Y, Kamoi S, Amada S, et al:Toward the development of a universal grading system for ovarian epithelial carcinoma. Testing of a proposed system in a series of 461 patients with uniform treatment and follow-up, Cancer 1998;82:893-901

• 18) Hacker N F, Berek JS, Lagasse LD, et al:Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 1983;61:413-420

• 19) Eisenkop SM, Friedman RL, Wang HJ:Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer:A prospective study. Gynecol Oncol 1998;69:103-108

• 20) Schwartz PE, Rutherford TJ, Chambers JT, et al:Neoadjuvant chemotherapy for advanced ovarian cancer:Long-term survival. Gynecol Oncol 1999;72:93-99

• 21) van der Burg ME, van Lent M, Buyse M, et al:The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 1995;332:629-634

• 22) Friedman RL, Eisenkop SM, Wang H-J:Second-look laparotomy for ovarian cancer provides reliable prognostic information and improves survival. Gynecol Oncol 1997;67:88-94

• 23) Tuxen MK, Strauss G, Lund B, et al:The role of second-look laparotomy in the long-term survival in ovarian cancer. Ann Oncol 1997;8:643-648

• 24) Rubin SC, Randall TC, Armstrong KA, et al:Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. Obstet Gynecol 1999;93:21-24

• 25) Podratz KC Kinney WK:Second-look operation in ovarian cancer, Cancer 1993;71:1551-1558

• 26) Carnino F, Fuda G, Gccone G, et al:Significance of lymph node sampling in epithelial carcinoma of the ovary. Gynecol Oncol 1997;65:467-472

• 27) McGuire WP, Hoskins WJ, Brady ME et al:Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6

• 28) Markman M:Intraperitoneal therapy of ovarian cancer. Semin Oncol 1998;25:356-360

• 29) Legros M, Dauplat J, Fleury J, et al:High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer:Long term results. J Clin Oncol 1997;15:1302-1309

• 30) Bolis G, Villa A, Guarnerio P, et al:Survival of women with advanced ovarian cancer and complete pathologic response at second-look laparotomy. Cancer 1996;77:128-131

• 31) 小山善之, 斎藤達雄:日本癌治療学会, 固形がん化学療法効果増強の判定基準. 日本癌治療学会誌, 1986;21:943-953

• 32) Nagele F, Petru E, Medl M, et al:Preoperative CA125:An independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet Gynecol 1995;86:259-264

• 33) Mogensen O:Prognostic value of CA125 in advanced ovarian cancer. Gynecol Oncol 1992;44:207-212

• 34) van der Burg ME, Lammes FB, van Putten WL, et al:Ovarian cancer:The prognostic value of the serum half-life of CA125 during induction chemotherapy. Gynecol Oncol 1988;30:307-312

• 35) Friedlander ML, Hedley DW, Taylor IW, et al:In Huence of cellular DNA content on survival in advanced ovarian cancer. Cancer Res 1984;44:397-400

• 36) Hedley DW, Friedlander ML, Taylor IW:Application of DNA now cytometry to paraffin-embedded archival material for the study of aneuploidy and its clinical significance. Gytometry 1985;6:327-333

• 37) Rodenburg CJ, Cornehsse CJ, Heintz P, et al:Tumor ploidy as a major prognostic factor in advanced ovarian cancer. Cancer 1987;59:317-323

• 38) Minguillon C, Schonborn I, Reles A, et al:EGF-Rand PCNA expression in ovarian carcinomas Correlation with classic prognostic factors. Gen Diagn Pathol 1996;141:197-201

• 39) Anttila M, Kosma VM, Ji H, et al:Clinical significance of alpha-catenin, collagen IV, and Ki-67 expression in epithelial ovarian cancer. J Clin Oncol 1998;16:2591-2600

• 40) Viale G, Maisonneuve P, Bonoldi E, et al:The combined evaluation of p53 accumulation and of Ki-67(MIBI) labelling index provides independent information on overall survival of ovarian carcinoma patients. Ann Oncol 1997;8:469-476

• 41) Leary JA, Edwards BG, Houghton CRS, et al:Amplification of HER-2/neu expression in advanced epithelial ovarian cancer. Int J Gynecol Cancer 1992;2:291-294

• 42) Slamon DJ, Godolphin W, Jones LA, et al:Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 1989;244:707-712

• 43) Berchuck A, Kamel A, Whitaker R, et al:Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990;50:4087-4091

• 44) Levesque MA, Katsaros D, Yu H, et al:Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 1995;75:1327-1338
  pubmed

• 45) Buttitta F, Marchetti A, Gadducci A, et al:p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas:A molecular and immunohistochemical study. Br J Cancer 1997;75:230-235

• 46) Eltabbakh GH, Belinson JL, Kennedy AW, et al:p53 Overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer. Cancer 1997;80:892-898

• 47) Mattern J, Stammler G, Koomagi R, et al:Spontaneous apoptosis in ovarian cancer:An favorable prognostic factor. Int J Oncol 1998;12:351-354

• 48) Diebold J, Baretton G, Felchner M, et al:bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas. Am J Clin, Pathol 1996;105:341-349

• 49) Herod JJ, Eliopoulos AG, Warwick J, et al:The prognostic significance of Bcl-2 and p53 expression in ovarian Carcinoma. Cancer Res 1996;56:2178-2184

• 50) Paley PJ, Staskus KA, Gebhard K, et al:Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 1997;80:98-106

P.317 掲載の参考文献

• 1) Scully RE:Tumors of the ovary and maldeveloped gonads. Atlas of Tumor Pathology, Fascicle 16. 1979, Armed Forces Institute of Pathology, Washington DC

• 2) Berek JS, Hacker NF:Nonepithelial ovarian and tubal cancers. Practical Gynecologic Oncology, 2nd ed(Berek JS, Hacker NF, eds). 1995, Williams & Wilkins, Baltimore

• 3) Slayton RE:Management of germ cell and stromal tumors of the ovary. Semin Oncol 1984;11:299-313

• 4) Cramer DW:Epidemiology and biostatistics. Practical Gynecologic Oncology(Berek JS, Hacker NF, eds). 1989;pp167-192, Williams & Wilkins, Baltimore

• 5) Gershenson DM, Wharton JT:Malignant germ cell tumors of the ovary. Ovarian Cancer(Albert DS, Surwit EA, eds). 1985;pp227-269, Martinus Nijihoff, Hingham

• 6) Manuel M, Katayama KP, Jones HW Jr:The age of occurrence of gonadal tumors in intersex patients with a Y chromosome. Am J Obstet Gynecol 1976;124:293-300

• 7) Dembo AJ, Bush RS, Brown TC:Clinicopathological correlates in ovarian cancer. Bull Cancer (Paris) 1982;69:292-297

• 8) Kurman RJ, Scardino PT, McIntire KR, et al:Malignant germ cell tumors of the ovary and testis:An immunologic study of 69 cases. Ann Clin Lab Sci 1979;9:462-466

• 9) Asadourian LA, Tayor HB:Dysgerminoma:An analysis of 105 cases. Obstet Gynecol 1969;33:370-379

• 10) Bjorkholm E, Lundell M, Gyftodimos A, et al:Dysgerminoma. The Radiumhemmet series 1927-1984. Cancer 1990;65:38-44

• 11) Buskirk SJ, Schiray MF, Podratz KC, et al:Ovarian dysgerminoma:A retrospective analysis of results of treatment, sites of treatment failure, and radiosensitivity. Mayo Clin Proc 1987;62:1149-1157

• 12) Gordon A, Lipton D, Woodrufr JD:Dysgerminoma:A review of 158 cases from the Emil Novak Ovarian Tumor Registry. Obstet Gynecol 1981;58:497-504

• 13) Malkasian GD Jr, Symmonds RE:Treatment of the unilateral encapsulated ovarian dysgerminoma. Am J Obstet Gynecol 1964;90:379-382

• 14) Kurman RJ, Norris HJ:Germ cell tumors of the ovary. Hum Pathol 1978;1:291-325

• 15) Berek JS, Hacker NF:Nonepithelial ovarian and tubal cancers. Practical Gynecologic Oncology, 2nd ed(Berek JS, Hacker NF, eds). 1995, Williams & Wilkins, Baltimore

• 16) Gershenson DM, Wharton JT, Kline RC, et al:Chemotherapeutic complete remission in patients with metastatic ovarian dysgerminoma. Cancer 1986;58:2594-2599

• 17) Thomas GM, Dembo AJ, Hacker NF, et al:Current therapy for dysgerminoma of the ovary. Obstet Gynecol 1987;70:268-275

• 18) Krepart G, Smith JP, Rutledge F, et al:The treatment for dysgerminoma of the ovary. Cancer 1978;41:986-990

• 19) Galhon HH, van Nagell JR Jr, Donaldson ES, et al:Ovarian dysgerminoma:Report of seven cases and review of the hterature. Am J Obstet Gynecol 1988;158:591-595

• 20) LaPolla JP, Benda J, Vigliotti AP, et al:Dysgerminoma of the ovary. Obstet Gynecol 1987;69:859-864

• 21) Loehrer PJ, Hui S, Clark S, et al:Teratoma following cisplatin-based combination chemotherapy for nonseminomatous germ cell tumors:A clinicopathological correlation. J Urol 1986;135:1183-1189

• 22) Williams SD, Blessing JA, Moor DH, et al:Cisplatin, vinblastine, and bleomycin in advanced and recurrent ovarian germ cell tumors. Ann Intern Med 1989;111:22-27

• 23) Williams SD, Blessing JA, Slayton RE, et al:Ovarian germ cell tumors:Adjuvant trials of Gynecologic Oncology Group. J Clin Oncol 1994;12:695-700

• 24) Bjanchi UA, Sartori E, Favalli G, et al:New trends in treatment of ovarian dysgerminoma (abstract). Gynecol Oncol 1986;23:246

• 25) Gershenson DM, Morris M, Cangir A, et al:Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin. J Clin Oncol 1990;8:715-720

• 26) Williams SD, Birch R, Einhorn LH, et al:Treatment of disseminated germ cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987;316:1435-1440

• 27) Williams SD, Blessing J, Hatch K, et al:Chemotherapy ofadvanced ovarian dysgerminoma trials of the Gynecologic Oncology Group(GOG). Proc Am Soc Clin Oncol 1990;9:155

• 28) Freeman C, Berg JW, Cutler SJ:Occurrence and prognosis of extranodal lymphomas. Cancer 1972;29:252-260

• 29) Williams SD:Treatment of germ cell tumors of the ovary. Semin Oncol 1991;18:292-296

• 30) Williams SD, Adcock L, Blessing J, et al:Treatment of ovarian germ cell tumors with cisplatin plus vinblastine plus bleomycin. Proc Am Soc Clin Oncol 1984;C683

• 31) Creasman WJ, Soper JT:Assessment of the contemporary management of germ cell mahgnancies of the ovary. Am J Obstet Gynecol 1985;153:828-834

• 32) Gershenson DM:Menstrual and reproductive function after treatment with combination chemotherapy for malignant ovarian germ cell tumors. J Clin Oncol 1988;6:270-275

• 33) Gershenson DM, Morris M, Cangir A, et al:Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin. J Clin Oncol 1990;8:715-720

• 34) Newlands ES, Southall PJ, Paradinas FJ, et al:Management of ovarian germ cell tumours. Textbook of Uncommon Cancer(Williams CJ, Kaikorian JG, Green MR, et al, eds). 1988;pp37-53, John Wiley & Sons, New York

• 35) Williams SD:Germ cell tumors. Ovarian Cancer(Ozols RF, ed). 1992;pp967-974, WB Saunders, Philadelphia

• 36) Berek JS, Hacker NF, Lagasse LD, et al:Survival of patients following secondary cytoreductive surgery in ovarian cancer. Obstet Gynecol 1983;61:189-193

• 37) Withers HR, Taylor JM, Maciejewski B:The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988;27:131-146

• 38) Xu FJ, Ramakrishnan S, Daly L, et al:Increased serum levels of macrophage colony stimulating factor in ovarian cancer, Am J Obstet Gynecol 1991;165:1356-1362

• 39) Norris HJ, Zirken HJ, Benson Wl:Immature(malignant)teratoma of the ovary:A clinical and pathologic study of 58 cases. Cancer 1976;37:2359-2372

• 40) Slayton RE:Management of germ cell and stromal tumors of the ovary. Semin Oncol 1984;11:299-313

• 41) Curry SL, Smith JP, Gallagher HS:Malignant teratoma of the ovary:Prognostic factors and treatment. Am J Obstet Gynecol 1978;131:845-849

• 42) Cangir A, Smith J, van Eys J:Improved prognosis in children with ovarian cancers following modified VAC(vincristine sulfate, dactinomycin, and cyclophosphamide)chemotherapy, Cancer 1978;43:1234-1238

• 43) Creasman WJ, Soper JT:Assessment of the contemporary management of germ cell malignancies of the ovary. Am J Obstet Gynecol 1985;153:828-834

• 44) Slayton RE, Hreshchyshyn MM, Silverberg SC, et al:Treatment of malignant ovarian germ cell tumors:Response to vincristine, dactinomycin and cyclophosphamide. Cancer 1978;42:390-398

• 45) Loehrer PJ, Elson P, Johnson DH, et al:A randomized trial of cisplatin plus etoposide with or without bleomycin in favorable prognosis disseminated germ cell tumors:An ECOG study. Proc Am Soc Clin Oncol 1991;10:540

• 46) Bajorin DF, Sarosdy MF, Bosl GJ, et al:A randomized trial of etoposide plus carboplatin versus etoposide plus cisplatin in patients with metastatic germ cell tumors. J Clin Oncol 1993;11:598-606

• 47) Gershenson DM, COpeland JL, Del Junco G, et al:Second-look laparotomy in the management of malignant germ cell tumors of the ovary. Obstet Gynecol 1986;67:789-794

• 48) Berek JS, Chung C, Kaldi K, et al:Serum interleukin-6 levels correlate with clinical disease status in epithelial ovarian cancer. Am J Obstet Gynecol 1991;164:1038-1043

• 49) Tseng CJ, Chou HH, Huang KG, et al:Squamous cell carcinoma arising in mature cystic teratoma of the ovary. Gynecol Oncol 1996;63:364-370

• 50) Kikkawa F, Ishikawa H, Tamakoshi K, et al:Squamous cell carcinoma arising from mature cystic teratoma of tha ovary:A clinicopathologic analysis. Obstet Gynecol 1997;89:1017-1022

• 51) Eltabbakh GH, Hempling RE, Recio FO, et al:Remarkable response of primary squamous cell carcinoma of the ovary to paclitaxel and cisplatin. Obstet Gynecol 1998;91:844-846

• 52) Karlen JR, Kastehc JE:Endodermal sinus tumor of the ovary:An improving prognosis. Gynecol Oncol 1980;10:206-216

• 53) Slayton RE, Park RC, Silverberg SC, et al:Vincristine, dactinomycin, and cyclophosphamide (VAC) in the treatment of malignant germ cell tumors of the ovary:A Gynecologic Oncology Group study(a final report). Cancer 1985;56:243-248

• 54) Williams SD, Blessing JA, Hatch K, et al:Chemotherapy of advanced dysgerminoma:Trials of the Gynecologic Oncology Group. J Clin Oncol 1991;9:1950-1955

• 55) Williams SD:Germ cell tumors. Ovarian Cancer(Ozols RF, ed). 1992;pp967-974, WB Saunders, Philadelphia

• 56) Newlands ES, Southall PJ, Paradinas FJ, et al:Management of ovarian germ cell tumours. Textbook of Uncommon Cancer (Williams CJ, Kaikorian JG, Green MR, et al, eds). 1988;pp37-53, John Wiley & Sons, New York

• 57) Kurman RJ, Norris HJ:Endodermal sinus tumor of the ovary. A clinicopathologic entity distinct from endodermal sinus tumor resembling embryonal carcinoma of the adults testis. Cancer 1976;38:2404-2419

• 58) Gerbie MV, Brewer JI, Tamimi H:Primary choriocarcinoma of the ovary. Obstet Gynecol 1975;46:720-723

• 59) Kurman RJ, Norris HJ:Malignant mixed germ cell tumors of the ovary. A clinical and pathologic analysis of 30 cases. Obstet Gynecol 1976;48:579-589

• 60) Gershenson DM:Management of early ovarian cancer. Germ cell and sex cord-stromal tumors. Gynecol Oncol 1994;55:S62-S72

• 61) Williams S, Wong LC, Ngan HYS:Management of ovarian germ cell tumors. Ovarian Cancer, Controversies in Management. 1998;pp399-415, Churchill Livingstone, New York

• 62) Gershenson DM:Update on malignant ovarian germ cell tumors. Cancer 1993;71:1581-1590

• 63) Williams SD, Copeland LJ, DelJnco G:Second-look laparotomy in the management of malignant germ cell tumors of the ovary. Obstet Gynecol 1986;67:789-794

• 64) Geisler JP, Goulet R, Foster RS, et al:Growing teratoma syndrome after chemotherapy for germ cell tumors of the ovary. Obstet Gynecol 1994;841719-721

• 65) Williams S, Bleesing JA, Liao S, et al:Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin:A trial of the Gynecologic Oncology Group. J Clin Oncol 1994;12:701-706

卵管の悪性腫瘍

P.324 掲載の参考文献

• 1) 小西郁生:婦人科病理の基礎知識としての女性性器の発生学. 図説産婦人科VIEW 25, 臨床病理学(藤井信吾, 寺島芳輝, 編). 1996;pp12-31, メジカルビュー社, 東京

• 2) Markman M, Zaino R, Fleming P, et al:Carcinoma of the fallopian tube. Principles and Practice of Gynecologic Oncology (Hoskins WJ, Perez CA, Young RC, eds), 2nd ed. 1997;pp1025-1038, Lippincott-Raven, Philadelphia

P.329 掲載の参考文献

• 1) Young RH, Scully RE:Pathology of tumors of fallopian tube and broad ligament. Gynecologic Oncology (Coppleson M, ed), 2nd ed. 1992;pp843-852, Churchill Livingstone, New York

• 2) 森脇昭介:卵管. 産婦人科病理学診断図譜(宮地 徹, 森脇昭介, 桜井幹己, 編), 第3版. 1998;pp322-347, 杏林書院, 東京

• 3) 上田外幸:卵管・広靱帯腫瘍. 診療のための婦人科腫瘍の臨床病理(滝 一郎, 上田外幸, 辻本正彦, 編). 1992;pp276-285, メジカルビュー社, 東京

• 4) Markman M, Zaino R, Fleming P, et al:Carcinoma of the fallopian tube. Principles and Practice of Gynecologic Oncology(Hoskins WJ, Perez CA, Young RC, eds), 2nd ed. 1997;pp1025-1038, Lippincott-Raven, Philadelphia

• 5) Deppe G, Malone JM Jr, Lawrence WD:Cancer of the fallopian tube. Female Genital Cancer (Gusberg SB, Shingleton HM, Deppe G, eds). 1988;pp427-434, Churchill Livingstone, New York

• 6) Hu CY, Taymor ML, Hertig AT:Primary carcinoma of the fallopian tube. Am J Obstet Gynecol 1950;59:58-67

• 7) Minato H, Shimizu M, Hirokawa M, et al:Adenocarcinoma in situ of the fallopian tube. A case report. Acta Crytol 1998;42:1455-1457

• 8) Stern J, Buscema J, Parmley T, et al:A typical epithehal proliferations in the fallopian tube. Am J Obstet Gynecol 1981;140:309-312

• 9) Uehira K, Hashimoto H, Tsuneyoshi M, et al:Transitional cell carcinoma pattern in primary carcinoma of the fallopian tube. Cancer 1993;72:2447-2456

• 10) Disaia PJ, Creasman WT:Carcinoma of the fallopian tube. Clinical Gynecologic Oncology (Disaia PJ, Creasman WT, eds), 4th ed. 1993;pp458-466, Mosby-Year Book, St Louis

• 11) Benedet JL, Miller DM:Tumors of fallopian tube:Clinical features, staging and management. Gynecologic Oncology(Coppleson M, ed), 2nd ed. 1992;pp853-860, Churchill Livingstone, New York

• 12) Eddy GL, Copeland LJ, Gershenson DM, et al:Fallopian tube carcinoma. Obstet Gynecol 1984;64:546-552

• 13) To N, Tsukamoto N, Maeda K, et al:Seven cases of primary adenocarcinoma of the fallopian tube. J Jpn Soc Cancer Ther 1989;24:16-20

P.334 掲載の参考文献

• 1) Dodson MG, Ford JH, Averette HE:Clinical aspects of fallopian tube carcinoma. Obstet Gynecol 1970;36:935-939

• 2) Creasman WT:Revision in classification by Internatinal Federation of Gynecology and Obstetrics. Am J Obstet Gynecol 1992;167:857-858

• 3) Hermanek P, Hutter RVP, Sobin LH, et al:UICC TNM Atlas, 4th ed. 1997;pp253-258, Springer, Berlin

P.336 掲載の参考文献

• 1) Disaia PJ, Creasman WT:Carcinoma of the fallopian tube. Clinical Gynecologic Oncology (Disaia PJ, Creasman WT, eds), 4th ed. 1993;pp458-466, Mosby-Year Book. St Louis

• 2) Benedet JL, Miller DM:Tumors of fallopian tube:Clinical features, staging and management. Gynecologic Oncology(Coppleson M, ed), 2nd ed. 1992;pp853-860. Churchill Livingstone. New York

• 3) Podratz KC, Podczaski ES, Gaffey TA, et al:Primary carcinoma of the fallopian tube. Am J Obstet Gynecol 1986;154:1319-1326

• 4) King A, Seraj IM, Thrasher T, et al:Fallopian tube carcinoma:A clinicopathological study of 17 cases. Gynecol Oncol 1989;33:351-355

• 5) Eddy GL, Copeland LJ, Gershenson DM, et al:Fallopian tube carcinoma. Obstet Gynecol 1984;64:546-552

• 6) To N, Tsukamoto N Maeda K, et al:Seven cases of primary adenocarcinoma of the fallopian tube. J Jpn Soc Cancer Ther 1989;24:16-20

• 7) 富樫かおり:卵管, 腟・会陰部の疾患. 婦人科疾患のMRI診断. 1990;pp229-242, 医学書院, 東京

• 8) Kawakami S, Togashi K, Kimura L et al:Primary malignant tumor of the fallopian tube:Appearance at CT and MR imaging. Radiology 1993;186:503-508

• 9) Markman M, Zaino R, Fleming P, et al:Carcinoma of the fallopian tube. Principles and Practice of Gynecologic Oncology(Hoskins WJ, Perez CA, Young RC, eds). 2nd ed. 1997;pp1025-1038, Lippincott-Raven, Philadelphia

• 10) Hirai Y, Chen J-T, Hamada T, et al:Clinical and cytologic aspects of primary fallopian tube carcinoma. A report of ten cases. Acta Crytol 1987;31:834-840

• 11) Takashina T, Ito E, Kudo R:Cytologic diagnosis of primary tubal cancer. Acta Crytol 1985;29:367-372

• 12) Niloff JM, Klug TL, Schaetzl E, et al:Elevation ofserum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix. Am J Obstet Gynecol 1984;148:1057-1058

P.342 掲載の参考文献

• 1) Podratz KC, Podczaski ES, Gafrey TA, et al:Primary carcinoma of the fallopian tube. Am J Obstet Gynecol 1986;154:1319-1326

• 2) Di Re E, Grosso G, Raspagliesi F, et al:Fallopian tube cancer:Incidence and role of lymphaticpread. Gynecol Oncol 1996;62:199-202

• 3) Tamimi HK, Figge DC:Adenocarcinoma of the uterine tube:Potential for lymph node metas-tases. Am J Obstet Gynecol 1981;141:132-137

• 4) Klein M, Rosen A, Lahousen M, et al:Lymphogenous metastasis inthe primary carcinoma of the fallopian tube. Gynecol Oncol 1994;55:336-338

• 5) Cormio G, Maneo A, Gabriele A, et al:Primary carcinoma of the falloplan tube:A retrospective analysis of 47 patients. Ann Oncol 1996;7:271-275

• 6) Rosen AC, Klein M, Lahousen M, et al:Primary carcinoma of the fallopian tube A retrospective analysis of 115 patients. Br. J Cancer 1993;68:605-609

• 7) Peters WA, Anderson WA, Hopkins MP:Results of chemotherapy in advanced carcinoma of the fallopian tube. Cancer 1989;63:836-838

• 8) Morris M, Gershenson DM, Burke TW, et al:Treatment of fallopian tube carcinoma with cisplatin, doxorubicin, and cyclophosphamide. Obstet Gynecol 1990;76:1020-1024

• 9) Maxson WZ, Stehmun FB, Ulbright TM, et al:Primary carcinoma of the fallopian tube:Evidence for activity of cisplatin combination therapy. Gynecol Oncol 1987;26:305-313

• 10) Cormio G, Maneo A, Gabriele A, et al:Treatment of fallopian tube carcinoma with cyclophos-phamide, adriamycin, and cisplatin. Am J Clin Oncol 1997;20(2):143-145

• 11) Pectasides D, Barbounis V, Sintila A, et al:Treatment of primary fallopian tube carcinoma with cisplatin-containing chemotherapy. Am J Clin Oncol 1994;17:68-71

• 12) Muntz HG, Tarraza HM, Goff BA, et al:Combination chemotherapy in advanced adenocarcinoma of the fallopian tube. Gynecol Oncol 1991;40:268-273

• 13) Klein M, Rosen A, Graf A, et al:Primary fallopian tube carcinoma-A retrospective survey of 51 cases. Arch Gynecol Obstet 1994;255:141-146

• 14) Schray MF, Podratz KC, Malkasian GD:Fallopian tube cancer:The role of radiation therapy. Radiother Oncol 1987;10:267-275

• 15) Roberts JA, Lifshitz S:Primary adenocarcinoma of the fallopian tube. Gynecol Oncol 1982;13:301-308

• 16) Kojs Z, Urbanski K, Reinfuss M, et al:Whole abdominal external beam radiation in the treatment of primary carcinoma of the fallopian tube. Gynecol Oncol 1997;65:473-477

• 17) Rosen AC, Reiner A, Klein M, et al:Prognostic factors in primary fallopian tube carcinoma. Gynecol Oncol 1994;53:307-313

• 18) Rose PG, Piver MS, Tsukada Y:Fallopian tube cancer. The Roswell Park experience. Cancer 1990;66:2661-2667

• 19) Hirai Y, Kaku S, Teshima H, et a:Clinical study of primary carcinoma of the fallopian tube:Experience with 15 cases. Gynecol Oncol 1989;34:20-26

• 20) Barakat RR, Rubin SC, Saigo PE, et al:Second-look laparotomy in carcinoma of the fallopian tube. Obstet Genecol 1993;82:748-751

• 21) Cormio G, Gabriele A, Maneo A, et al:Second-look laparotomy in the management of fallopian tube carcinoma. Acta Obstet Gynecol Scand 1997;76:369-372

• 22) Takeshima N, Hirai Y, Yamauchi K, et al:Clinical usefulness of endometrial aspiration cytology and CA-125 in the detection of fallopian tube carcinoma. Acta Crytol 1997;41:1445-1450

• 23) Tokunaga T, Miyazaki K, Matsuyama S, et al:Serial measurement of CA-125 in patients with primary carcinoma of the fallopian tube. Gynecol Oncol 1990;36:335-337

• 24) Rosen AC, Klein M, Rosen HR, et al:Preoperative and postoperative CA-125 serum levels in primary fallopian tube carcinoma. Arch Gynecol Obstet 1994;255:65-68

• 25) Benedet JL, White GW, Fairey RN, et al:Adenocarcinoma of the fallopian tube-Experience with 41 patients. Obstet Gynecol 1977;50:654-657

• 26) Denham JW, Maclennan KA:The management of primary carcinoma of the fallopian tube-Experience of 40 cases. Cancer 1984;53:166-172

• 27) Frigerio L, Pirondini A, Pileri M, et al:Primary carcinoma of the fallopian tube. Tumori 1993;79:40-44

• 28) Pettersson F, ed:FIGO Annual Report, vol 22. 1995, FIGO, Stockholm

• 29) Rosen AC, Sevelda P, Klein M, et al:A comparative analysis of management and prognosls in stage I and II fallopian tube carcinoma and epithelial ovarian cancer, Br J Cancer 1994;69:577-579

• 30) Barakat RR, Rubin SC, Saigo PE, et al:Cisplatin-based combination chemotherapy in carcinoma of the fallopian tube. Gynecol Oncol 1991;42:156-160

• 31) Rosen AC, Graf AH, Klein M, et al:DNA-ploidy in primary fallopian tube carcinoma using image cytometry. Int J Cancer 1994;58:362-365

• 32) Heselmeyer K, Hellstrom A-C, Blegen H, et al:Primary fallopian tube:Comparative genomic, hybridization reveals high genetic instability and a specific, recurring pattern of chromosomal aberrations. Int J Gynecol Pathol 1997;17:245-254

• 33) Lacy MQ, Hartmann LC, Keeney GL, et al:C-erb-B-2 and p53 expression in fallopian tube carcinoma. Cancer 1995;75:2891-2896

• 34) Wolfson AH, Trahns KS, Greven KM, et al:Adenocarcinoma of the fallopian tube:Results of amulti-institution retrospective analysis of 72 patients. Int J Radiat Oncol Biol Phys 1998;40:71-76

• 35) Semrad N, Watring W, Fu Y-S, et al:Fallopian tube adenocarcinoma:Common extraperitoneal recurrence. Gynecol Oncol 1986;24:230-235

• 36) McMurray EH, Jacobs AJ, Perez CA, et al:Carcinoma of the fallopian tube:Management and sites of failure. Cancer 1986;58:2070-2075

腹膜の悪性腫瘍

P.356 掲載の参考文献

• 1) Lauchlan S:The secondary mullerian system. Obstet Gynecol Surv 1972;27:133-146

• 2) 小西郁生:腹膜の良性腫瘍・類腫瘍病変. 新女性医学大系39, 産婦人科の良性腫瘍. 1999;pp333-346, 中山書店, 東京

• 3) Clement PB:Diseases of the peritoneum. Blaustein's Pathology of the Female Genital Tract (Kurman RJ, ed), 4th ed. 1994;pp647-703, Springer-Verlag, New York

• 4) Battifora H, McCaughey WTE:Tumors of the serosal membranes. Atlas of Tumor Pathology. 1995;pp17-88. Armed Forces Institute of Pathology, Washington DC

• 5) 河合俊明:悪性中皮腫の病理. 病理と臨床1996;14:1352-1360

• 6) Daya D, McCaughey WTE:Well-differentiated papillary mesothelioma of the peritoneum. A clinicopathologic study of 22 cases. Cancer 1990;65:292-296

• 7) Wagner JC, Sleggs CA, Marchand P:Diffuse pleural mesothelioma and exposure in the North Western Cape Province. Br J Ind Med 1960;17:260-271

• 8) Roggli VL:Malignant mesothelioma and duration of asbestos exposure:Correlation with tissue mineral fibre content. Ann Occup Hyg 1995;39:363-374

• 9) Sakai K, Hisanaga N, Huang J, et al:Asbestos and non-asbestos fiber content in lung tissue of Japanese patients with malignant mesothelioma. Cancer 1994;73:1825-1835

• 10) Goldblum J, Hart WR:Localized and diffuse mesotheliomas of the genital tract and peritoneum in women. A clinicopathological study of nineteen true mesothelial neoplasms, other than adenomatoid tumors. multicystic mesotheliomas and localized fibrous tumors. Am J Surg Pathol 1995;19:1124-1137

• 11) Clement PB, Young RH, Scully RE:Malignant mesotheliomas presenting as ovarian masses:A report of nine cases, including two primary ovarian mesotheliomas. Am J Surg Pathol 1996;20:1067-1080

• 12) Asensio JA, Goldblatt P, Thomfold NR:Primary malignant peritoneal mesothelioma. A report of seven cases and a review of the literature. Arch Surg 1990;125:1477-1481

• 13) Daya D, McCaughey WTE:Pathology of the peritoneum:A review of selected topics. Semin Diagn Pathol 1991;8:277-289

• 14) Whitaker D, Shilkin KB:Diagnosis of pleural malignant mesothelioma in life A practical approach. J Pathol 1984;143:147-175

• 15) 伊藤 仁, 梅村しのぶ, 長村義之:中皮腫の鑑別診断. 病理と臨床1996;14:1393-1400

• 16) Motoyama T, Watanabe T, Okazaki E, et al:Immunohistochemical properties of malignant mesothelioma cells in histologic and cytologic specimens. Acta Cytol 1995;39:164-170

• 17) Antman K, Osteen RT, Klegar KL, et al:Early peritoneai mesothelioma:A treatable malignancy. Lancet 1985;ii:977-980

• 18) Lauchlan SC:The secondary mullerian system revisited. Int J Gynecol Pathol 1994;13:73-79

• 19) Sampson JA:Endometrial carcinoma of the ovary, arising in endometrial tissue in that organ. Arch Surg 1925;10:1-72

• 20) Scott RB:Malignant changes in endometriosis. Obstet Gynecol 1953;2:283-289

• 21) Zhou J, Iwasa Y, Konishi I, et al:Papillary serous carcinoma of the peritoneum in women. A clinicopathologic and immunohistochemical study. Cancer 1995;76:429-436

• 22) Gilks CB, Bell DA, Scully RE:Serous psammocarcinoma of the ovary and peritoneum. Int J Gynecol Pathol 1990;9:110-121

• 23) Feuer GA, Shevchuk M, Calanog A:Normal-sized ovary carcinoma syndrome. Obstet Gynecol 1989;73:786-792

• 24) 山崎輝行, 波多野久昭, 鈴木章彦, ほか:Normal-sized ovary carcinoma syndrome 14例の病理組織学的解析. 日本産科婦人科学会雑誌1995;47:27-34

• 25) Morrow CP, Curtin JP, Townsend DE:Synopsis ofgynecologic oncology, 4th ed. 1993;pp241-242, Churchill Livingstone, New York

• 26) Ronnett BM, Shmookler BM, Diener-West M, et al:Immunohistochemical evidence supporting the appendiceal origin of pseudomyxoma peritonei in women. Int J Gynecol Pathol 1997;16:1-9

• 27) Gompel C, Silverberg SG:Pathology in Gynecology and Obstetrics, 4th ed. 1994;p442, JB Lippincott, Philadelphia

• 28) Russel P:Surface epithelial-stromal tumors of the ovary. Blaustein's Pathology of the Female Genital Tract(Kurman RJ, ed), 4th ed. 1994;pp724-733. Springer-Verlag, New York

• 29) Piver MS, Lele SB, Patsner B:Pseudomyxoma peritonei:Possible prevention of mucinous ascites by peritoneal lavage. Obstet Gynecol 1984;64:95S-96S

• 30) Geisler JP, Goulet R, Foster RS, et al:Growing teratoma syndrome after chemotherapy for germ cell tumors of the ovary. Obstet Gynecol 1994;84:719-721